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ABSTRACT
Dopamine D2 Receptor Priming Enhances Dopaminergic Response to Amphetamine in
the Nucleus Accumbens: Role of the D1 and D2 Receptors.
by
Kimberly Norris Huggins
In past work, we have shown neonatal quinpirole (dopamine D2/D3 agonist) treatment produces
a significant increase in dopamine D2 receptor sensitivity, a phenomenon known as D2 receptor
priming. Dopamine D2 receptor priming is common in psychosis. Male and female rats were
administered quinpirole (1mg/kg) or saline from postnatal days 1-11 and raised to adulthood
(P60). As adults, rats were administered d-amphetamine sulfate (1mg/kg) or saline every other
day for 14 days. Approximately 10 min before each amphetamine or saline injection, animals
were administered the D1 antagonist SCH 23390 (0.1 mg/kg), the D2 antagonist eticlopride (0.1
mg/kg) or saline. After both injections, rats were placed in a locomotor arena and activity was
analyzed for a 10-min period. Results indicated that D2-priming enhanced locomotor activation
effects to amphetamine in both males and females, with females demonstrating higher levels of
behavioral activation. SCH 23390 blocked amphetamine sensitization in both males and
females to levels below saline controls, whereas eticlopride was more effective in blocking
amphetamine sensitization in males as compared to females, although eticlopride did block
elevations of behavioral activation in D2-primed males and females. Seven to 10 days after
sensitization, microdialysis was performed and amphetamine produced a five-fold increase in
dopamine overflow in the nucleus accumbens compared to non D2-primed rats administered
amphetamine. Both D1 and D2 antagonism were effective at blocking amphetamine-induced
increases in dopamine overflow. These results show that neonatal quinpirole treatment
enhances behavioral activation and dopamine overflow, but there appear to be sex differences
in the D2 as compared to D1 response to behavioral activation produced by amphetamine.
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CHAPTER 1
INTRODUCTION
Substance use disorder comorbidity in mental illness is widespread, impacting up
to 50% of patient populations (Siegfried 1998). Schizophrenia is one of the most
common dually diagnosed mental illnesses (Cuffel 1996). Dopamine has been
implicated in psychosis as being increased in its activity (Schmitt et al. 2009). This
increased activity has been debated, but most agree that this neurotransmitter plays a
primary role in both motor behavior and drug reinforcement. In our laboratory, we have
used a rodent model of increased dopaminergic activity to analyze drug abuse. This
model is focused on increasing the sensitivity of dopamine D2-like receptors in the
brain, that is accomplished through developmental treatment with a dopamine D2/D3
agonist quinpirole. Previous work using this model has shown a potentiated effect of
amphetamine on dopamine overflow within the dorsal striatum (Nowak et al. 2001). This
effect is consistent with findings in schizophrenia (Abi Dargham et al. 1996; Laurelle et
al. 1996). Thus, these results suggest that psychotics who use amphetamine may
demonstrate a sensitized dopamine response to amphetamine. If this is the case, then
this increased dopamine response may be producing a stronger euphoric reaction to
stimulant drugs in this population, and this may be the basis for the increased usage of
these drugs in this population.
This study uses these past findings as a springboard to analyze the effects of
subchronic amphetamine treatment on locomotor sensitization and accumbal dopamine
as well as to identify sex differences on these measures. In addition, the roles of
dopamine D1 and D2 dopamine receptors in sensitization and the dopaminergic
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response to amphetamine are studied. These findings may lead to identifying receptor
mechanisms of this effect, be the first study to analyze the roles of D1 and D2 receptors
in both males and females in this phenomenon, that may lead to further understanding
the significant health problem of substance abuse in psychosis.
Dopamine D2 Receptor Priming Model
Kostrzewa and colleagues have shown that quinpirole, a dopamine D2/D3
receptor agonist, administered during neonatal development results in increases in
dopamine D2 receptor sensitivity throughout the animal‟s lifetime. This is a phenomenon
that has been referred to as priming of the D2 receptor. Previous work has shown that
quinpirole treatment from postnatal days 1-11, 1-21, or 21-35 results in an increase of
dopamine D2 receptor sensitivity that persists throughout the animal‟s lifetime
(Kostrzewa et al. 1990, 1991, 1993a, 1993b, 1995). This change is independent of a
change in D2 receptor number. In recent work, we have shown that the neonatal
quinpirole treatment model has produced several behavioral changes that are
consistent with findings in schizophrenics.
First, as mentioned above, acute amphetamine administration to adult rats
neonatally treated with quinpirole produced a robust increase in dopamine overflow in
the striatum greater than an increase seen by amphetamine administration alone
(Nowak et al. 2001). This is consistent with findings from clinical studies using
functional magnetic resonance imaging (fMRI), positron emission tomography (PET),
and single positron emission computer tomography (SPECT) in schizophrenic patients
that have shown a pronounced increase of amphetamine-induced dopamine release in
the dorsal striatum as well as a decrease of amphetamine-induced dopamine depletion
9

in drug-naïve schizophrenic patients, indicating a regulatory problem with dopaminergic
neurotransmission (Lanzenberger and Kasper 2005, Laruelle, et al. 2005).
Second, a hallmark of psychosis is a deficit in sensorimotor gating, that is most
commonly analyzed using the behavioral paradigm prepulse inhibition (PPI). PPI is a
psychophysiological index of sensorimotor gating. One of the more consistent
behavioral findings in schizophrenics is that PPI is impaired, that has also been
suggested to be related to cognitive impairments known to exist in this population
(Geyer 1998). In medicated schizophrenia patients, greater PPI impairment during the
attended prepulse has been associated with heightened positive symptoms related to
the disturbance (Dawson et al. 2000). We have shown that in previous work that adult
rats that were neonatally treated with quinpirole demonstrated deficits in sensorimotor
gating as tested by PPI (Maple 2005).
Third, neonatal quinpirole treatments have been shown to produce long-term
cognitive impairment in both adolescents and adulthood (Brown et al. 2002; 2004;
2005). Cognitive impairment is present in schizophrenia and has been suggested to be
the „core‟ of behavioral deficits present in the disorder (Elvevag and Goldman 2000).
This suggestion follows the discovery that 94% of patients with schizophrenia have
neurocognitive deficits in the areas of memory, attention, and executive function and
may help predict the functional outcome in schizophrenia (Waldo et al. 1994; Green
1998). Often, these deficits constitute one of the key features in a schizophrenia
diagnosis (Peuskens et al. 2005).
Fourth, possibly the most important neurophysiological finding consistent
with psychosis is that neonatal quinpirole treatment produces a significant decrease in
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RGS9 expression in the nucleus accumbens, striatum, and frontal cortex of adult rats
(Maple et al. 2007). RGS9 is a regulator of G-protein signaling at the D2 receptor, and
when active RGS9 increases the rate of termination of events at the D2 receptor,
ultimately resulting in a lower activity in the D2 receptor (Rahman et al. 2003). Thus, a
decrease in RGS9 expression is consistent with an increased signaling at the D2
receptor. Importantly, significant decreases in RGS9 have been shown in these same
brain areas post-mortem in human psychotic patients (Seeman et al. 2007).
Fifth, subchronic treatment with the atypical antipsychotic olanzapine has been
shown to alleviate cognitive deficits and long-term priming of the D2 receptor produced
by neonatal quinpirole treatment (Thacker et al. 2006). Olanzapine is in the atypical
class of antipsychotics and blocks the D2 receptor with some affinity as well at the 5HT2 receptor. Olanzapine is one of the most often prescribed antipsychotics for
schizophrenia. Our laboratory has shown that sub-chronic olanzapine treatment given
twice daily for 1 month in adulthood modestly alleviated deficits in Morris water maze
performance produced by neonatal quinpirole treatment (Thacker et al. 2006).
Importantly, this treatment also alleviated the significant increase in yawning produced
in rats neonatally treated with quinpirole to control levels after a 7-day washout.
Yawning behavior is a dopamine D2/D3 receptor mediated event (Cooper, et al. 1989;
Collins, et al. 2005). These data demonstrate that not only is D2-priming likely primarily
responsible for these behavioral effects, but that antipsychotic treatments are effective
in alleviating cognitive impairment, that is also consistent with clinical findings in
schizophrenics (Gurpegui et al. 2007).
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Sixth, another neurochemical consistency in this model is that neonatal
quinpirole treatments have been shown to result in neurotrophic factor abnormalities
comparable to observations in human schizophrenic patients. Studies from this lab
have shown a significant decrease in nerve growth factor (NGF) and brain-derived
neurotrophic factor (BDNF) protein in the hippocampus of D2-primed animals as
compared to control treated animals. Further, significant decreases in hippocampal
NGF and BDNF protein produced by neonatal quinpirole treatment were reversed by
olanzapine, and brain tissue was not taken until after an 8-day washout. Interestingly,
sub-chronic olanzapine treatment failed to alleviate significant decreases of genetic
expression of NGF or BDNF in the hippocampus or frontal cortex as measured through
real-time PCR (RT-PCR; Brown et al. 2008), suggesting that the positive effects of
olanzapine on neurotrophic factors in this model may be focused on changes in protein
and not genetic expression. This is consistent with findings that have shown nonmedicated schizophrenic patients have an overall decrease in NGF and BDNF
expression, hypothetically involved in neurodevelopmental abnormalities in the
hippocampus and frontal cortex known to be present in schizophrenia (Aloe et al. 2001,
Parikh et al. 2003).
These six consistencies demonstrate the validity of the model relative to
psychosis. However, this model should be used with some caution. Although an
increase in dopamine D2 receptor sensitivity is a hallmark of psychosis, it is not the only
change responsible for the array of behavioral abnormalities known to exist within this
disorder. For example, it is also well-known that there is hypoactivity at the
glutamatergic N-methyl-D-aspartate (NMDA) receptor that is important for many of the
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behavioral and neurochemical abnormalities mentioned above (Labrie and Roder,
2009), and may be important in the increased substance abuse within this population.
Further, there are also important changes in the serotonergic system that also may play
a role in substance abuse in psychosis as well, and we do not yet know whether these
neurotransmitter systems are also disrupted in the same manner within this model.
Regardless, increases in D2 receptor sensitivity are a hallmark of psychosis, and we
have shown several important consistencies between this model and the human
condition.
Psychosis
Psychotic symptoms can occur in several behavioral disorders including
schizophrenia, bipolar disorder, obsessive-compulsive disorder, degenerative brain
disease, as well as following the abuse of steroids. While these diseases exhibit unique
characteristics, one common biomarker is a putative increase in the high-affinity states
of dopamine D2 receptors in the central nervous system as a property of psychosis
(CNS; Seeman et al. 2005). The D2 dopamine receptor, originally denoted as the
antipsychotic receptor, has been examined for changes in density following various
treatments, most commonly denervation of the neostriatum and long-term
administration of antipsychotics (Seeman et al. 1980; Schwarting and Huston 1996,).
Most importantly, increases in D2 receptor sensitivity are the basis of the dopamine
hypothesis of schizophrenia, as all antipsychotic drugs block the D2 receptor.
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Dopamine Hypothesis of Schizophrenia
The first formulation of the dopamine (DA) hypothesis resulted from early
observations that activation of the dopamine system by psychostimulants produced a
behavioral phenomenon that is consistent with psychosis, and that dopamine
antagonists relieved this psychotic state (Rossum 1966). These observations led to the
hypothesis that hyperactivity of DA transmission was responsible for the disorder. The
classic dopamine hypothesis was further bolstered from the correlation between clinical
doses of antipsychotic drugs and their potency at blocking DA D2 receptors as well as
the psychotogenic effects of DA-enhancing drugs (Creese et al. 1976; Lieberman et al.
1987; Seeman 1987).
The current hypothesis suggests that an imbalance in DA with hyperactive
subcortical mesolimbic projections results in hyperstimulation of D2 receptors. This
increased sensitivity of D2 receptor causes positive symptoms and hypoactive
mesocortical DA projections to the prefrontal cortex (PFC) results in hypostimulation of
D1 receptors, that ultimately results in negative symptoms and cognitive impairment
(Tzschentke 2001). Weinberger has suggested that the two areas of DA imbalance
may be related because a deficiency in mesocortical DA function may translate into
disinhibition of mesolimbic DA activity (1987).
Dopamine has been a major focus of the research involving the mechanisms of
schizophrenia. Much of the literature suggests a combined impact of glutamatergic and
dopaminergic systems as the mechanism underlying psychosis, and some studies
have focused on dysfunction in the glutamate system. While each system has shown
results lending merit towards and understanding of the disease, it remains difficult to
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reconcile the hypoglutamatergic and hyperdopaminergic hypotheses. It is most
plausible that the heterogenous symptomology of the disease arise from different
neurotransmitter systems. The dopamine hypothesis is no longer the only accepted
theory as the basis of schizophrenia but still holds validity in the study of many aspects
of the disease.
Modeling Psychosis
Using Animal Models and Their Importance
A recent focus of neuroscience research and of the National Institutes of Health
has been on the formation of models of human diseases (NIH Roadmap, 2005).
Overall, animal models add value in basic sciences research by allowing investigators
to elucidate aspects of complex disease or mechanistic pathways. Animal models are
limited by the inability to study the long-term progression of a disease and the lack of
direct homology between animal systems and the human system (Woodruff and
Baisden 1994). However, animal models may be useful for development and discovery
of new and more effective treatments for neurological disorders (Woodruff & Baisden
1994). In many cases, animal models of neurological disease and dysfunction are used
to model one aspect of the disorder whether it be behavioral, neurochemical, or
neuropathological. This can be extremely useful because it can be informative about the
contribution of this behavioral or neurochemical abnormality to the disease or disorder,
although the entire disorder is not modeled in the animal. McKinney and Brunney (1969)
proposed three criteria for validating an animal model of similar inducing conditions,
similar behavioral states, and common mechanisms in an animal model. The D2priming model used in this study reaches all three of these criteria, as mentioned above.
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McKinney and Brunney (1969) concluded that the higher number of criteria the model
achieves means that the model has increased validity. Therefore, the model used here
has increased validity relative to the psychotic state, although we have not yet shown
whether there are changes in non-dopaminergic systems that are consistent with the
disorder. Therefore, to research a clinical condition in humans, an animal model that
does not necessarily have all aspects of the disorder can be used for a more thorough
examination of the disease.
Animal Models of Psychosis
Modeling schizophrenia and/or psychosis poses several difficulties as a result of
the heterogeneity of the presentation of symptoms. Animal models are used in studying
schizophrenia, psychosis as an aspect of mental illness, drug-induced psychoses, and
bipolar disorder that may include a psychotic component. The psychotic component of
schizophrenia has garnered much attention adding to the understanding of psychosis in
general. Schizophrenia is a severe and chronic mental illness affecting approximately
1% of the population. Symptoms of schizophrenia typically emerge during adolescence
or early adulthood (American Psychiatric Association, 2008). Symptoms are usually
classified into three categories: positive (hallucinations, delusions, thought
disorganization), negative (anhedonia, social withdrawal), and cognitive (deficits in
attention and memory) (Carpenter and Buchanan, 1994). Hallucinations can be
auditory, visual, tactile, or olfactory in nature. Auditory hallucinations include hearing
voices and sounds that are not audible to outside observers (American Psychiatric
Association Diagnostic and Statistical Manual 2000). Negative symptoms include a
flattened affect or lack of emotion, intonation or facial expression, as well as anhedonia
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(absence of pleasure and lack of motivation or ability to follow through with plans).
Clinical diagnoses recognize impaired social relationships, difficulty in maintaining selfcare, and impaired social and professional interactions as part of the disorder. Previous
research suggests that alterations in several neurotransmitter systems are involved in
the pathophysiological process leading to the expression of these symptoms, though no
clear etiology of schizophrenia has been shown.
Other Rodent Models of Schizophrenia
Several animal models have been used to investigate aspects of schizophrenia.
The importance of animal research is evident in the ability to generalize findings using
animal subjects to the human health condition. Generalization of schizophrenic research
from animal to human is possible through using behavioral tasks with specific task
demands, testing parameters, and mechanisms of the behavioral deficits involved in the
disorder. There have been several attempts to model schizophrenia using rodent
models. All of these models have clinical relevance to the disorder through mimicking
neurochemical abnormalities known to be present in schizophrenia. However, it is also
important to realize that all of these models have weaknesses that relate to the
complexity of the neurochemical aberrations in this disorder.
NMDA Receptor Model
A primary abnormality in schizophrenia is related to the glutamatergic system.
The glutamate hypothesis suggests that glutamatergic dysfunction is associated with
the NMDA receptor. Research has found that a glutamatergic receptor subtype, the Nmethyl-D-aspartate (NMDA) receptor, is less responsive in schizophrenics than it is in
controls (Tsai and Coyle 2002, Coyle 2006). Based on NMDA hypofunction,
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researchers have focused on producing NMDA hypofunction through acute
administration of phencyclidine (PCP) or ketamine, that are both noncompetitive
antagonists of the N-methyl-D-aspartate (NMDA) glutamate receptor. Studies have
shown that NMDA receptor hypofunction results in positive and negative symptoms
similar to those found in schizophrenia as well as cognitive deficits in normal humans
(Snyder 1980, Javitt and Zukin 1991, Tamminga 1998). NMDA receptors are a major
subtype of glutamate receptors that mediate slow excitatory postsynaptic potentials
(EPSPs) that are considered critical for the expression of behaviors including
associative learning, working memory, and attention, functions that are impaired in
schizophrenia (Blair et al. 2001).

PCP has also been shown in rats and humans to

closely mimic the positive, negative, and cognitive symptoms observed in schizophrenia
(Krystal et al. 1994, Carlsson et al. 2004, Lisman et al. 2008). Neuronal
synchronization, that is thought to depend partly on glutamatergic regulation over
GABAergic neurons, is impaired in schizophrenia and correlates with perceptual,
speech, and other cognitive processes (Spencer et al. 2003, Ford et al. 2007, Lewis et
al. 2005, Mohler 2007, Gaspar et al. 2009). Using a novel object recognition paradigm,
rats treated with PCP were shown to produce robust reductions in time spent with the
novel object versus the familiar object, a measure of working memory (Grayson, et al.
2007). The novel object recognition task, that is used to measure working memory, was
developed based on the natural propensity of rats to explore novel objects (Ennaceur
and Delacour 1988). A reduction in working memory following PCP administration
helps to establish some validity of the model in terms of investigating cognitive deficits
that may exist in schizophrenia. This model would not withstand the criteria for face
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validity as many of the symptoms of schizophrenia are subjective in nature and cannot
truly be replicated in an animal model. However, glutamatergic manipulations have
value as a predictive model as such manipulations induce behavioral or neurochemical
changes similar to schizophrenia and are alleviated by similar therapeutic treatments.
Psychostimulant Model
Acute administration of psychostimulants is known to produce a robust increase
in dopamine release, and increased dopaminergic activity as a result of psychostimulant
treatment was the original basis of the dopamine hypothesis of schizophrenia (Duncan
et al. 1999). Increases in dopamine function, as mentioned above, are known to be
common in schizophrenia. In the psychostimulant model, animals are tested while under
the influence of the drug to analyze behavioral changes related to robust increases in
the dopamine system (Tilson & Rech 1973, Lacriox et al. 2000).
Two behavioral measures used in an effort to model schizophrenia that seem to
have clinical relevance are latent inhibition and prepulse inhibition (PPI). Latent
inhibition (LI) is a process by that exposure to a stimulus of little or no consequence
prevents conditioned associations with that stimulus from being formed. Latent
inhibition has been interpreted as a representation of the lack of the ability to ignore
irrelevant information, a deficit observed in schizophrenic patients (Solomon et al. 1981,
Killcross et al. 1994). Disruption in LI has been demonstrated in schizophrenia (Gray et
al. 1992, 1995, Lipp et al. 1992). The operational processes can be viewed as
analogous across species (Lubow and Gewritz 1995). Prepulse inhibition (PPI) is a
psychophysiological index of sensorimotor gating that has been used with schizophrenic
patients. PPI is defined as the reduction of the amplitude of the startle reflex (usually
19

the eyeblink reflex in humans) when a “prepulse” that is non-startling precedes the
startle pulse (Blumenthal 1999). PPI has been found to be impaired in schizophrenic
patients. For example, using treatments of amphetamine with and without DA
antagonists, it was shown that the medial prefrontal cortex is involved in mediating
prepulse inhibition but is not involved in latent inhibition (Lacroix et al. 2000). Thus,
cortical changes proposed in schizophrenia may be modeled using PPI measurements
but not LI. Although these treatments are helpful in elucidating the effects of short-term
increases in DA release, they are unable to recreate the long-term dopaminergic effects
seen in schizophrenia. Therefore, the acute administration of a pharmacological
substance may be useful as a predictive model but does not meet the constraints for
face validity or construct validity.
Neonatal Ventral Hippocampal Lesion (NVHL) Model
Likely the most prominently used model of schizophrenia has focused on
neonatal damage of the ventral hippocampus in rats (Lipska et al. 1993, Chambers et
al. 1996, Wan et al. 1996, Brake et al. 1999, Grecksch et al. 1999). Past results have
shown that lateral ventricles are larger and that the hippocampus is smaller in volume in
schizophrenics. The main objective of this model is to disrupt hippocampal
development that is a hallmark of neuropathology known to be present in schizophrenia
(Falkai and Bogerts 1986; Bogerts et al. 1990; Suddath et al. 1990; Eastwood and
Harrison 1995; 1998; Weinberger 1999). The disruption of hippocampal development
also results in the changes of the cortical and subcortical circuitry of brain areas that
make connections to the hippocampal formation. These neonatal lesions are intended
to involve regions of the hippocampus that directly project to the prefrontal cortex,
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including the ventral hippocampus proper and ventral subiculum that corresponds to the
anterior hippocampus in humans (Jay et al. 1989; Carr and Sesack 1996). These
lesions produce changes in hippocampal-frontal cortex connectivity consistent with
schizophrenia as well as changes in behavioral deficits in latent inhibition, prepulse
inhibition, social responses, and cognitive performance (Swerdlow et al. 1996, Lipska et
al. 1995, Chambers et al. 1996, Grecksch et al. 1999). Further, these changes do not
emerge until after adolescence, consistent with the presentation of schizophrenia in
humans (Lipska et al. 1993, Chambers et al. 1996, Becker et al. 1999, Lipska et al.
1995). The lesions result in the clear destruction of ventral portions of the
hippocampus including parts of the CA1, CA2, and CA3 regions and portions of the
ventral subiculum (Swerdlow et al. 2001). A major weakness of this model involves the
blatant neuronal damage created by the lesion. This disconnection of neurons is not
exhibited in schizophrenia and the impact of such disruption outside of the targeted
effects may be yet unknown.
Comorbidity of Substance Abuse
Drug addiction is viewed as a complex neuroadaptive process through that drugs
of abuse alter cellular and molecular aspects of neural function to increase or decrease
the responsiveness of various behavioral effects through their mediating circuits (White
2002). The dopaminergic system is most directly implicated in the positive reinforcing
effects of all drugs of abuse. The ability of addictive drugs to enhance dopamine
neurotransmission, primarily in the mesolimbic dopaminergic system, has been
documented widely across various classes of abused drugs (Wise and Bozarth 1987,
Koob 1992, White 1996, Spanagel and Weiss 1999).
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Substance Abuse in Schizophrenia
Substance abuse in schizophrenics carries consequences that further impact
schizophrenic patients. Research has shown that among individuals diagnosed with
schizophrenia between 33% and 66% meet the criteria for at least one substance
related disorder in their lifetime (Meuser et al. 1992). Schizophrenic patients with
concurrent substance abuse experience more frequent hospitalization episodes
(Swofford et al. 2000). The interactions of the drugs of abuse with the neuropathology
of schizophrenia exacerbate symptoms and interfere with drug treatments (Burnette et
al. 1997, Dervaux et al. 2001). Therefore, substance abuse in schizophrenics
complicates the proper medication of these patients (Siris et al. 1998).
Two hypotheses have been proposed to explain the increased rate of substance
abuse in schizophrenics. The first hypothesis suggests that schizophrenic patients
abuse psychostimulant drugs in an attempt to alleviate aspects or symptoms of the
disease (Akerele and Levin 2002, Gregg et al. 2007). Studies have suggested that
nicotine use may help alleviate sensory gating abnormalities and attentional deficits
produced by schizophrenia (Le Duc and Mittleman 1995, Adler et al. 1998).

The

second hypothesis focuses on the use of drugs to relieve negative side effects of the
neuroleptic treatment of the disease. Antipsychotic medications have been used in
schizophrenia treatment since the early 1950s. While these medications are helpful in
allaying positive symptoms, antipsychotic treatment can also lead to disabling extrapyramidal motor symptoms such as parkinsonianism, dystonia, and dyskinesia. Studies
have attempted to address whether the use of psychostimulants in schizophrenic
patients exacerbates extrapyramidal symptoms or is sought to alleviate those symptoms
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(Dixon et al. 1991, Gao et al. 2008, Potvin et al. 2009). Results have shown that
patients with a dual diagnosis of schizophrenia and substance abuse exhibit worse
extra-pyramidal symptoms than either disorder singly (Duke et al. 1994, Bailey et al.
1998, Potvin et al. 2009). Clinical studies have not been able to determine the order of
occurrence in the relationship between substance abuse in schizophrenics and
extrapyramidal symptoms. Confounding factors include a varied dosage of
antipsychotics by individual, a variety of abused drugs often within a single subject, and
the potential symptoms of psychostimulant withdrawal that may mimic some of the
extrapyramidal symptoms.
Another mechanism of studying the relationship between substance abuse and
schizophrenia is the self-report. Within the self-reporting literature, several reasons for
use have been examined: intoxication effects, social reasons, dysphoria relief, and
alleviation of psychotic symptoms and to mitigate extrapyramidal symptoms. Between
35% and 95% of subjects reported using drugs or alcohol for the intoxicating effects
(Dixon et al. 1991, Addington and Duchak 1997, Baker et al. 2002). Between 8% and
81% of schizophrenic patients cited social reasons as the cause for their drug use (Test
et al. 1989, Dixon et al. 1991, Warner et al. 1994). Up to 86% reported using drug or
alcohol to relieve dysphoria (Test et al. 1989, Dixon et al. 1991, Warner et al. 1994). In
using drugs or alcohol to alleviate or cope with psychotic symptoms, results indicated
that up to 42% of subjects responded affirmatively (Addington and Duchak 1997, Dixon
et al. 1991, Test et al. 1898). Between 0 and 48% reported using alcohol or drugs to
alleviate negative side effects of medication (Test et al. 1989, Dixon et al. 1991, Warner
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et al. 1994, Gregg et al. 2007). Overall, there is no clear understanding of the full
relationship of the dual diagnosis of schizophrenia and substance abuse.
Dopaminergic Mechanisms of Amphetamine
Amphetamine is an indirect dopamine agonist known to increase extracellular
dopamine in the striatum and nucleus accumbens (Wise 1996). Amphetamine induces
increases in dopamine overflow and prevents dopamine reuptake through inhibition of
the dopamine transporter. In addition to inhibiting dopamine reuptake, amphetamine
causes the release of dopamine from the presynaptic terminals (Seiden et al. 1993).
Amphetamine-induced dopamine release occurs by two mechanisms: calciumdependent vesicular release and impulse-dependent or transporter-mediated release.
Impulse-dependent release is independent and has little calcium dependence that is
why often amphetamine is stated to increase dopamine overflow as compared to
dopamine release (Hurd and Ungerstedt 1989, Pierce and Kalivas 1997).
Amphetamine can cross the plasma membrane via lipophilic diffusion as well as
being a substrate for the dopamine transporter (DAT) (Zaczek et al. 1991a, 1991b).
Once inside the neuron amphetamine (AMPH) displaces dopamine from the vesicles
into the cytoplasm (Sulzer and Rayport 1990). From the cytoplasm, DA can be
released into the extracellular space by the dopamine transporter (Floor and Meng
1996). Studies have shown that both the depletion of dopamine from secretory vesicles
and the reversal of DAT-mediated transport are necessary for the effect of
amphetamine on overflow in dopaminergic neurons (Jones et al. 1998).
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Behavioral Sensitization
One common behavioral test to analyze the effects of amphetamine on
behavioral activation is behavioral locomotor sensitization. Behavioral sensitization is
the progressive and long-lasting augmentation of certain behaviors following repetitive
stimulant drug treatment (Segal and Mandell 1974, Kalivas and Stewart 1991, Robinson
and Berridge 1993). Sensitized behaviors may occur with a shorter latency, higher
intensity, or at a lower dose following repeated treatment with stimulant drugs including
amphetamine or cocaine (Segal et al. 1980). Behavioral sensitization is a two-step
process, development and expression. The development or initiation of amphetamine
sensitization involves dopamine D1 and glutamate receptor activation within the ventral
tegmentum and substantia nigra (Kalivas and Alesdatter 1993, Wolf et al. 1995, Bijou et
al. 1996). Expression is defined as the neuronal alteration arising from the initiating
process that mediates the augmented behavioral response and that is mediated by the
nucleus accumbens (Wolf 1998). Alterations include an increase in the non-NMDA
glutamate AMPA receptor surface expression resulting from dopaminergic modulation in
the nucleus accumbens following psychostimulant sensitization (Pierce 1996, Boudreau
and Wolf 2005). Measurements of locomotor activity including vertical, horizontal and
rotational are typically used in experiments analyzing behavioral sensitization.
Behavioral changes resulting from addictive drugs resemble behavioral
responses elicited by natural reward, though the reward of addictive drugs has the
power to supplant all other goals, making the drug reward a higher priority to the
organism than all other rewards including food. The rewarding properties of addictive
drugs putatively require an increased dopaminergic release from midbrain ventral
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tegmental area neurons onto nerves in the nucleus accumbens (Wise and Bozarth
1987, Koob and Bloom 1988, Di Chiara 1998). Ventral tegmental area dopamine
projections to other forebrain areas such as the prefrontal cortex and the amygdala also
play a role in shaping drug-taking behaviors (Everett et al. 1999). Structural similarities
in the nucleus accumbens shell and amygdala have led some to postulate the nucleus
accumbens shell to be an extension of the amygdala, the region of the brain thought to
be responsible for emotional and rewarding behaviors (Everritt et al. 1991, Meredith et
al. 2002). Despite the varying targets and chemical composition of the various classes
of addictive drugs, they all cause an increase in synaptic dopamine within the nucleus
accumbens. In order for addictive drugs to produce reward, they must utilize dopamine
in a similar manner (Kelley and Berridge 2002). It has been hypothesized that addictive
drugs have competitive advantages over natural stimuli by producing far greater levels
of dopamine release resulting in prolonged stimulation (Kelley and Berridge 2002).
Modeling Substance Abuse in Animals
Psychostimulants possess the ability to stimulate DA transmission in the nucleus
accumbens (Di Chiara 2002). Studies using amphetamine have shown that the
dopamine system is critically important for development and expression of behavioral
sensitization (Kalivas et al. 1993a, 1993b). Acute or repeated amphetamine exposure
results in augmented dopamine overflow in the striatum and nucleus accumbens (NAcc)
in vivo (Wilkinson et al. 1993) and in vitro (Castandeda et al. 1988). Local
administration of amphetamine in the NAcc in animals previously sensitized to
amphetamine also produces increased DA overflow in NAcc and striatum (Pierce and
Kalivas 1996).

26

Dopamine System
Dopamine is estimated to constitute up to 80% of the total catecholamine content
in the brain, but the total number of dopaminergic cells is relatively small (Lindvall et al.
1984, Williams and Goldman-Rakic 1998). Three major divisions of dopaminergic
pathways innervate the forebrain and basal ganglia (Bjorklund and Lindvall 1984, Lewis
et al. 1998, Tzchentke 2001). These cell groups are designated as A8, A9, and A10
and generally corresponds to the DA cells of the substantia nigra (A9), ventral
tegmental area (A10), and the retrorubral area (A8) (Porrino and Goldman-Rakic 1982,
Williams and Goldman-Rakic 1998). Dopaminergic neurons are functionally involved in
higher motor execution, goal-directed behaviors including motivation, reward learning,
prediction, and working memory (Egan and Weinberger 1997, Lewis et al. 1998).
Impairment of these neurons results in neurological and psychiatric disorders
(Goldman-Rakic 1998).
Ascending dopaminergic fibers innervate a large number of subcortical and
cortical structures including the neocortex. Structures of the basal ganglia, particularly
the striatum, receive the most dense dopaminergic input (Boyson et al. 1986). Within
the neocortex, sensory areas are sparsely innervated while cortical areas such as the
primary motor cortex, prefrontal cortex, and anterior cingulate cortex are more densely
innervated by dopaminergic neurons (Berger and Gaspar 1994, Durstewitz et al. 1999).
This innervation reflects the role of dopamine in motivation, reward, motor function, and
executive function as compared to involvement in sensory systems.
There are several major dopaminergic pathways. The nigrostriatal system
originates in the substantia nigra pars compacta, the ventral tegmental area, and the
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retrorubral nucleus and projects to the caudate, putamen, globus pallidus, and nucleus
accumbens. The nigrostriatal pathway is important in motor control (Feldman et al.
1996). The mesolimbic system contains the circuitry involved in reward and originates
in the ventral tegmental area, substantia nigra, and retrorubral nucleus and projects to
the septum, amygdala, hippocampus, nucleus of the diagonal band, anterior olfactory
nucleus, nucleus accumbens, and olfactory tubercles (Fuxe 1985). The mesocortical
pathway originates in the ventral tegmental area, projects to the frontal cortex, and is
essential to the normal cognitive function of the prefrontal cortex (Feldman et al. 1986).
The majority of neurons in the NAcc are GABAergic and they project
predominately to the ventral tegmental area (VTA) and the ventral pallidum, regions
thought to be involved in the rewarding effects of most drugs of abuse (Self 2004). The
GABA system modulates both dopamine and glutamate transmission within the NAcc
and its areas of projection. Glutamatergic neurons converge on the same dendritic
spines of medium-size spiny GABA neurons as dopaminergic afferents without making
direct connections between the glutamatergic and dopaminergic projections (Segovia
and Mora 2001). Pulvirenti and colleagues (1991) suggest that glutamate from the
NAcc modulates stimulation at the level of the NAcc by interacting with the integrated
output of the region.
Dopamine Receptors
All known dopamine receptors are G-protein coupled, slow acting metabotropic
receptors that functionally modulate other receptor systems and/or ion channels
(Missale et al. 1998). Activation of these receptors, through intracellular cascades,
modulates properties of synapses and postsynaptic neurons. There are five dopamine
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receptor subtypes belonging to two families: the D1-like receptors and the D2-like
receptors. Functionally, these two types of receptors have opposing actions in the
cellular cascade. The D1-like receptors activate adenylyl cyclase resulting in an
increase of cyclic adenosine monophosphate (cAMP). The D2-like receptors inhibit
adenylyl cyclase resulting in a decreased concentration of cAMP (Greengard et al.
1999). The D1-like receptor family contains the D1 and D5 dopamine receptors, while
the D2-like receptor family contains the D2, D3, and D4 dopamine receptors.
The distribution of the D1 receptors has been mapped by in vitro autoradiography
using several agonists and antagonists. The greatest densities of D1 receptors are
found in the caudate, putamen, NAcc, and olfactory tubercle. Lower densities are found
in the neocortex, thalamus, cerebellum, hippocampus, septum, and hypothalamus
(Boyson et al. 1986, Dawson et al. 1986, Wamsley et al. 1992, Duffy et al. 2000).
Activation of D1 dopamine receptors is necessary for the induction of
sensitization by amphetamine in the VTA (Vezina 1996). Sensitization produced by
amphetamine in the ventral tegmental area is blocked by systemic injection of the D1
antagonist SCH23390 (Vezina 1996). Pre-amphetamine administration of selective
dopamine D1 or D2 antagonists have been shown to block amphetamine sensitization,
although the D1 receptor has been shown to play a more important role than the D2,
although this has not been thoroughly investigated (Vezina and Stewart 1989; 1996).
Dopamine D1 receptors have a higher affinity for dopamine than D2 receptors (Seeman
and Van Tol 1994). Systemic pretreatment with the D1 receptor antagonist SCH23390
inhibited the locomotor activating effects of repeated psychostimulant administration
and prevented the development of sensitization (Hummel and Unterald 2002). Results
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have also shown location specificity in the role of D1 receptors in sensitization. It
appears that noncortical D1 receptors are more important than cortical D1 receptors in
the development of sensitization, intracortical administration of D1 antagonist failed to
significantly affect psychostimulant induced locomotor activity or stereotypy, whereas
D1 antagonist treatment within the ventral tegmental area has been shown to block
sensitization (Beyer and Steketee 2002; Vezina 1996).
Dopamine D2 receptors are most densely located in the caudate, putamen,
nucleus accumbens, olfactory tubercle, substantia nigra pars compacta, and the
glomular layer of the olfactory bulbs with less dense populations in the central nucleus
of the amygdala, lateral septum, superior colliculus, molecular layer of the
hippocampus, and the entorhinal cortex (Boyson et al. 1986, Pinto and Sesack 2008).
Amphetamine induced sensitization may involve the D2 receptor both
presynaptically at the autoreceptor, a receptor located on the presynaptic neuron
terminal that serves as a part of a feedback loop in signal transduction, and at
postsynaptic D2 receptors. Daily amphetamine treatment has been shown to produce a
subsensitization of dopamine D2 autoreceptors in the ventral tegmental area (Seutin et
al. 1991, Wolf et al. 1993, Muscat et al. 1996). The subsensitization of D2 autoreceptors
occurs in conjunction with an increased activity of A10 dopaminergic neurons in the
ventral tegmental area (Pierce et al. 1995).

The increased activity in A10 neurons may

result in priming of postsynaptic dopamine neurons (Ackerman and White 1992, Henry
et al. 2000, Hopf et al. 2007). In response to amphetamine treatment, the postsynaptic
signal transduction is linearly correlated to extracellular dopamine concentration. It has
been suggested that at lower dopamine concentrations presynaptic binding may be
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dominate to postsynaptic binding (Kuczenski and Segal 1989, Ren et al. 2009).
Systemic administration of selective D2 antagonist (Vezina, 1989) has been shown to
not affect amphetamine sensitization, and a less selective D2-like antagonist,
eticlopride, that was also used in this study, has been infused into the ventral tegmental
area and also shown to block amphetamine sensitization. However, there are no data
on the systemic effects of eticlopride on amphetamine sensitization or its effects on
dopamine overflow.
An important issue of the effects of neonatal quinpirole is the pre- and postsynaptic effects of this drug treatment. Quinpirole is a dopamine D2/D3 agonist and D2
as well as D3 receptor are located both pre- and post-synaptically. Blockade of
postsynaptic receptors is generally considered to be the primary effect of neuroleptic
administration and will result in a reduction of dopaminergic transmission. For some
dopaminergic neurons, this immediate effect is opposed by compensatory feedback
mechanisms (Galloway 1990). The blockade of presynaptic autoreceptors by
neuroleptics results in an increased synthesis and release of dopamine from the
dopaminergic terminal, thereby overcoming the blockade of dopamine receptors
produced by the antagonist. There are also long-loop neuronal feedback pathways that
can be involved. For example, during periods of enhanced postsynaptic dopamine
receptor stimulation, these loops exert negative feedback effects on dopamine cell
firing, whereas the blockade of postsynaptic receptors would produce a compensatory
increase in dopamine cell firing (Benkert et al. 1992). Within the mesolimbic system,
data have shown that either the D1 agonist SKF 38393 or the D2 agonist quinpirole can
increase extracellular dopamine levels in the nucleus accumbens in a dose-dependent
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fashion without affecting dopamine levels in the ventral tegmental area (Rahman and
McBride 2001). Further, coadministration of SKF 38393 and quinpirole produce a
concomitant reduction in the extracellular levels of dopamine in the nucleus accumbens
as well as in the ventral tegmental area. Blockade of either the D1 or D2 receptor was
sufficient to reverse the effect of the coinfusion of agonists. These results suggest that
the activation of dopamine D1 or D2-like receptors are independently able to regulate
local terminal dopamine release in the nucleus accumbens, but stimulation of both
subtypes is required for activation of the negative feedback pathway to the ventral
tegmental area (Rahman and McBride 2001).
Sex Differences
Studies of sex differences in schizophrenia have concluded that women tend to
have a less intrusive course of illness including less hospitalizations and better social
functioning than men (Mueser and McGurk 2004). Studies have suggested that the
later onset of schizophrenia in women is resultant of the effects of estrogen on D2
receptors in the central nervous system (CNS). Studies have shown that estrogen
treatment reduced the affinity of sulpiride to the D2 receptor, leading to the conclusion
that estrogen treatment reduced the sensitivity of D2 receptors (Häfner et al. 1991a).
Studies have also revealed an elevated vulnerability threshold to schizophrenia in
women that persists until menopause, implicating the modulatory role of estrogen on the
dopamine system (Häfner et al. 1998). In female schizophrenic patients, a correlation
was found that the higher the estradiol level, the more 'normal functioning' the behavior
was judged to be (Reicher-Rössler et al. 1994). Additionally, it has been suggested that
estrogen might act on NMDA receptors as well, both in the menstrual cycles and over a
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longer period of time. This effect could contribute to the protective effect of estrogen in
schizophrenia given the implications of the involvement of glutamate within the disease
(Woolley and McEwen 1994).
Sex Hormones and Psychostimulant Abuse
Previous studies have indicated gender differences in the neurobiological
response to psychostimulants and in behavioral sensitization (Becker 1999, Bowman et
al. 1999). Sex differences are present for all phases of drug abuse: initiation,
escalation of use, progression to addiction, withdrawal, and relapse (Haaren and Meyer
1991, Van Etten et al. 1999, Lynch and Carroll 2002, Carroll et al. 2004). While the
rates of drug abuse are currently lower in women than men, once addicted to a drug,
women show more difficulty in cessation of use than men (Lynch and Carroll 2002,
Breese et al. 2005). In women, the subjective effects of psychostimulants, particularly
d-amphetamine, vary across the menstrual cycle. Subjective positive effects including
euphoria, increased energy, and intellectual efficiency were reported when estradiol
levels are higher than progesterone levels during the follicular phase (Becker and Hu
2008). Administration of estradiol during the follicular phase further increases the
subjective effects of d-amphetamine (Justice and De Wit 2000).
The acute behavioral response to psychomotor stimulants in rodents reflects
both the sex difference (including locomotor response, self-administration, and drug
sensitivity) and the modulatory role of gonadal hormones in males and females (Becker
and Beer 1986, Van Hatesveldt et al. 1989, Basser et al. 2000). Behavioral
sensitization can also be differentially affected by gonadal steroid hormones. For
example, females exhibit more robust sensitization than do intact males (Robinson et al.
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1981, Robinson et al. 1982, Camp and Robinson 1988, Forgie and Stewart 1994).
Following ovariectomy of female rats, the expression of sensitization to AMPH is
attenuated or completely suppressed (Robinson et al. 1982, Sicar and Kim 1999).
Estradiol treatment in ovariectomized rats enhances locomotor sensitization induced by
AMPH or cocaine (Peris et al. 1991; Forgie and Stewart 1994). Studies have shown
that female rats exhibit increased locomotor response to amphetamine treatment versus
male rats (Becker 1999, Melnick and Dow-Edwards 2001). Female rats also show
greater and more prolonged stereotyped behavior following amphetamine treatment and
more amphetamine induced rotational behavior than males (Beatty and Holzer 1978,
Robinson et al. 1980).
There are no sex differences in the number or binding characteristics of striatal
D2 DA receptors in adult rats (Hruska and Dilbergeld 1980, Levesque and Di Paolo
1988, Teicher et al. 2003).

Striatal D2 receptor density increases at the onset of

puberty but is decreased significantly by adulthood in males. Periadolescent females
show less overproduction and pruning of striatal D1 and D2 receptors (Andersen and
Teicher 2000). There are sex differences in basal and amphetamine (AMPH)stimulated striatal DA release in the absence of gonadal hormones. Results from in
vivo microdialysis in freely moving rats show that the basal extracellular concentration of
DA is twice as high in the striatum of castrated males as in ovariectomized females
(Xiao and Becker 1994). Enduring differences in D1 receptor density may play a role in
the greater incidence of substance abuse in males given the implied role of the D1
system in the development of addiction (Naldonado et al. 1993).
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In cultured striatal neurons from embryonic mice, estradiol administration induces
changes in adenylate cyclase activity that are stimulated by D1 and D2 dopamine
receptor agonists by modifying the G-protein coupling process (Maus et al. 1989a,
Maus et al. 1989b). Administration of physiological concentrations of estradiol to striatal
slices directly stimulated DA release in vitro (Becker 1990). Estradiol works directly on
the striatum to induce changes in DA release and DA receptor activity. Further studies
have indicated that the effect of estradiol on striatal DA release may be mediated
indirectly by the effect of estradiol on GABAergic striatal neurons (Becker and Hu 2008).
Estrus Cycle and Psychostimulants
It has been hypothesized that dopamine function in females may be influenced
significantly by the fluctuation of ovarian hormones throughout the estrus cycle (Becker
1990). The estrus cycle of the female rat has three stages: proestrus, diestrus, and
estrus. This cycle typically recurs every 4 days (Marcondes et al. 2002). Ovarian
hormone fluctuations induce variation in behavioral and neurochemical responses to
psychostimulant drugs. Behavioral estrus occurs simultaneous to vaginal estrus and
therefore an increased estrogen level is present during this time as well a behavioral
estrus. During behavioral estrus in female rats, amphetamine-induced dopamine
release in the striatum and amphetamine behaviors are greater than on others days of
the estrus cycle (Becker et al. 1980, Becker et al. 1982, Becker et al. 1989, Becker et al.
2001). Studies have shown that a greater behavioral response is elicited from female
rats with stimulation of the striatal dopamine system during behavioral estrus as
compared to diestrus (Becker et al. 1982, Kalivas and Stewart 1991).
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Goals of This Study
Research on psychosis has indicated a high comorbidity of substance abuse and
psychosis. In those cases with comorbid substance abuse and schizophrenia the drugs
of choice are often psychostimulants and more specifically amphetamine or nicotine.
Therefore, further investigations into amphetamine sensitization in a putative model of
psychosis may offer insight of the mechanisms involved in comorbidity.
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CHAPTER 2
METHODS
This study uses neonatal quinpirole treatments from postnatal days 1-11 to
produce life-long changes consistent with some aspects of schizophrenia. Past studies
by Kostrzewa and colleagues (Nowak et al. 2001) have shown that neonatal quinpirole
treatment results in long-term increases in sensitivity of D2-like receptors. Adult animals
were then treated with either SCH23390 (a D1 receptor antagonist) or eticlopride (a D2like receptor antagonist) in an amphetamine behavioral sensitization design, with
animals given amphetamine or saline every other day over a 14-day period for a total of
7 drug treatments. Approximately 15 mins before each amphetamine or saline
treatment, a D1 antagonist (SCH23390), D2 antagonist (eticlopride), or saline will be
given to produce blockade of D1 and D2 receptors.
One day after sensitization is complete, a guide cannula will be surgically
implanted. Six to 8 days later, an amphetamine or saline challenge will be given.
However, a microdialysis probe will be placed into the nucleus accumbens core during
this challenge. On the challenge, animals will be given the same antagonist and
adulthood drug treatment that they received during behavioral testing on the challenge.
The goals of this study are to determine the role of the dopamine D1 and D2
receptors in the amphetamine-induced sensitization of rats neonatally treated with
quinpirole. Additionally, the study investigated potential sex effects of treatments on
females versus males. It is hypothesized based on past findings (Vezina 1989) that a
dopamine D1 antagonist would block amphetamine behavioral sensitization and no
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increase in locomotor activity would be seen following amphetamine sensitization. In
terms of the effects on dopamine overflow, it is hypothesized that D1 antagonism will
completely block the effects of amphetamine on dopamine overflow based on past
findings (Vezina 1996).
Additionally, a D2/D3 antagonist was hypothesized to reduce sensitization versus
saline treated control animals, although not to the level of animals given a D1
antagonist. The D2 receptor has been shown to not play a role in amphetamine
sensitization (Vezina 1996, others), but antagonism of the D3 receptor has been shown
to block amphetamine sensitization (Richtand et al. 2003). Based on this finding, it is
hypothesized that antagonist treatment wit the D2/D3 antagonist eticlopride will reduce
sensitization although not to the levels of D1 antagonism. It is hypothesized that pretreatment with eticlopride will actually potentiate the effects of amphetamine on
dopamine overflow based on the fact that eticlopride will block the D2 and D3
autoreceptors presynaptically, that should enhance dopamine release at the synapse.
Information in Figure 1 describes the treatment groups for this study, beginning with
neonatal treatment and including antagonist treatment as well as adult drug treatment.
Neonatal treatments were given once daily P1-11. The antagonist treatments were
administered approximately 15 minutes prior to the adult drug treatment. Following
adult drug treatment (10 minutes after administration), animals were placed in locomotor
arenas for testing.
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Figure 1 Diagram of drug treatments throughout the study. White boxes denote treatments during neonatal periods, prior
to weaning. Gray boxes denote treatments involved in behavioral sensitization and microdialysis. AMPH denotes
treatment with d-amphetamine.
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Subjects and Housing of Animals
A total of 10 untimed pregnant female Sprague Dawley rats were ordered from
Harlan, Inc. (Indianapolis, IN). Once animals arrived, they were housed separately for 7
days. Throughout the experiment animals were kept in an Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC) accredited colony with a 12h
light/dark cycle. All behavioral testing and neurochemical sampling occurred during the
light cycle. After an initial quarantine period, the pregnant rats were housed singly until
the pups were born, that was counted as postnatal day (P)0. Following birth, pups were
housed with the female dams until P21. On P22, rats were weaned and housed in
groups according to their neonatal treatments throughout adolescence and during
amphetamine sensitization behavioral testing. Upon surgical implantation of the guide
cannula, rats were singly housed for the remaining duration of the experiment.
Neonatal Drug Treatment
Animals were injected with either quinpirole (1 mg/kg) or saline at a total volume
of 1% of their body weight during treatment, P1-11. Following injections, the needle
was left in place for approximately 5 seconds to avoid loss of drug as a result of
capillary action resulting from needle removal.
Drugs
All drug were administered through intraperitoneal (ip) injection, with the
exception of postoperative ketoprofen that was given by intramuscular injection. For
neonatal drug treatment and the yawning test quinpirole HCl (Sigma-Aldrich, St. Louis,
MO) was administered. A dose of 1.0 mg/kg of the D2/D3 agonist quinpirole (or saline)
was injected intraperitoneally (ip) for neonatal treatment. Previous studies have shown
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this dose to be sufficient to produce an increase in dopamine D2 receptor sensitivity that
will persist throughout the animal‟s lifetime (Kostrzewa et al. 1991, 1993, 1995). During
behavioral sensitization a dose of 1.0 mg/kg d-amphetamine injected ip (Sigma-Aldrich,
St. Louis, MO) was administered every other day over a 14-day period to adult rats.
Previous data indicated that a dose of 1.0 mg/kg amphetamine was sufficient to
produce increased dopaminergic overflow in animals neonatally treated with quinpirole.
Additionally, this dose of amphetamine has been shown to produce behavioral
sensitization (Hooks et al. 1992, Cadoni et al. 2002, Vanderschuren et al. 2003). For
receptor antagonism, the D1 antagonist SCH 23390 (7-Chloro-8-hydroxy-3-methyl-1phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride) was administered at a dose
of 0.1 mg/kg (ip injection), that has been shown to be effective at blocking sensitization
to a dose of 1.0 mg/kg amphetamine (Vezina 1996). The D1 antagonist, SCH 23390
has a >1000 times higher affinity at the D1 receptor as compared to the D2 receptor
(Seeman and Grigoriadis, 1987). For D2 antagonism, a dose of 1.0 mg/kg eticlopride
was administered. This eticlopride dose has been shown to block behavioral changes
produced by 1.0 mg/kg doses of amphetamine (Vezina 1996). Eticlopride has >2.5x10 6
more affinity at the D2 receptor than the D1 receptor (Vezina 1996). The vehicle for all
drug preparations was a 0.9% saline solution.
Yawning Behavior
At approximately P60, a time point equating to young adulthood in the rat,
animals were tested for yawning behavior. Yawning has been shown to be a dopamine
D2-like receptor mediated event. Studies have shown that this behavior may be
mediated either by D2 (Cooper et al. 1989) or the D3 receptor subtype (Collins et al.
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2005), although both of these receptors are members of the D2 receptor family. Prior to
testing, all animals were administered quinpirole (100 μg/kg) and placed in an inverted
cage without bedding. Bedding can result in chewing behavior that interferes with the
observance and expression of the yawning behavior. Previous work indicated this dose
of quinpirole resulted in the most robust yawning response within a 1-hr period for each
subject (Nowak et al. 2001). An observer blind to treatment condition observed the
behavior for the period of 1 hour.
Habituation to the Locomotor Arena
Beginning at approximately 61 days of age, animals began habituation to the
locomotor arena. For habituation, animals were placed in the locomotor arena for 10
minutes every 2nd day for 1 week. Immediately before each habituation session rats
were administered an ip injection of saline. Animals were injected with saline to control
for any locomotor effect that may exist as a result of the stress produced by the
injection.
Behavioral Sensitization
Behavioral sensitization began approximately 2 days after the last habituation
session. For each sensitization trial, approximately 10 minutes before injection of saline
or amphetamine, rats were injected with the D1 receptor antagonist SCH23390, the D2
receptor antagonist eticlopride, or saline. Ten minutes before placement in the arena,
rats were administered with amphetamine (1.0 mg/kg) or saline based on group
assignment. Once in the arena, horizontal activity was monitored for 10 minutes using
an automated behavioral scanning system (AnyMaze, Stoelting Co, Dale Wood, IL ).
For horizontal activity measurements, the AnyMaze software digitally superimposes a 5
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x 5 cm grid on the floor of the arena. Each time an animal crosses a line on the grid it is
counted as a horizontal activity count. The total number of activity counts for each 10min trial provided a quantification of the total horizontal activity.
As an additional behavioral measure turning behavior, both clockwise and
counterclockwise was analyzed. Previous work has shown that rats demonstrate a
drug-induced turning preference that is consistent in direction and correlated with the
magnitude of turning when rats are retested with the same dose of the same drug
(Becker et al. 1982, Glick et al. 1983). Turning behavior has been shown to be an
effective measure of striatal function lending some additional information to the current
study design (Robinson 1984).
Surgical Procedure for Implantation of Guide Cannula
On the day following the completion of amphetamine behavioral sensitization, a
guide cannula (Bioanalytical Systems, Lafayette, IN) was surgically implanted, aimed at
the nucleus accumbens core. Animals were first injected ip with a mixture of ketamine
and xylazine for surgery to allow placement of the animal into the stereotaxic frame.
However, the ratio of the ketamine/xylazine mixture was different based on the sex of
the animal. Males were injected with a mixture of 60 mg/kg ketamine:8 mg/kg xylazine
and females were injected with a mixture of 50 mg/kg ketamine: 10 mg/kg xylazine.
These different doses helped to account for potential differences in metabolism of the
anesthetic agents between male and female rats and to maintain proper levels of
anesthesia during surgery (Zambricki and Dalecy, 2004). After the animal was
anesthetized, the head was shaved and placed into the ear bars of a Kopf (Kopf
Instruments, Inc., Tunjunga, CA) stereotaxic frame, and the nose of the animal was
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inserted into a Kopf stereotaxic mask (Model 906, Kopf Instruments, Inc., Tunjunga,
CA). The mask was connected to an anesthesia machine (JD Medical VT-100,
Phoenix, AZ) that delivered an isoflurane/O2 mixture (1-1.5%) at a rate of 2 L/min. An
incision was made on the midline of the scalp and the covering connective tissue
removed from the skull. A small hole was drilled through the skull at the following
coordinates relative to Bregma: Anterior/Posterior = +1.0 mm, Medial/Lateral = +/-1.2
mm. The guide cannula was inserted through this opening to a dorsal level of 6 mm
below bregma. These coordinates, taken from the stereotaxic atlas of Paxinos and
Watson (1986) correspond to the dorsal location of the nucleus accumbens core. Three
other small burr holes were drilled for the anchor screws and screws were attached to
the skull. Dental acrylic was mixed (1.0 g powder, 2.0 mL methyl methacrylate) and
poured onto the skull and around the anchor screws to secure the cannula in place.
Once the acrylic was dry, the incision was sutured closed and wound clips were placed
over the sutures. After the wound was closed, the animal was removed from the
stereotaxic frame and placed in an empty polycarbonate cage on a heating pad.
Additionally, to ease postoperative discomfort, all animals were injected intramuscular
with ketoprofen (5 mg/kg) and 10 cc of saline to replenish fluids lost during the surgical
procedure. The animals were allowed to recover and returned to their home cage once
ambulatory. Following microdialysis, the brains were analyzed by dissection for proper
probe placement. Animals with incorrect probe placement were not included in the
results.
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Estrus Cycle
On each day of testing as well as on the day of microdialysis, the state of estrus
cycle of female rats was verified. A sample of cells was taken from the animal's vaginal
lumen using a saline-moistened cotton swab. The sample was placed on a slide and
analyzed under a microscope (Olympus microscope BH series). The stage of the
estrus cycle was used as a variable in initial analysis of locomotor activity and dopamine
overflow to determine if the stage of the estrus cycle impacted locomotor activity and/or
dopamine overflow in the nucleus accumbens.
Microdialysis and Amphetamine Challenge
Seven-10 days after amphetamine sensitization was complete, a microdialysis
pin probe (Bioanaltyical, Lafayette, IN) was implanted through the guide cannula with
2.0 mm of active membrane exposed. Prior to insertion of the probe, it was washed
with artificial CSF for a period of 1 hour. Once the animal was attached to the probe,
artificial CSF [145 mM sodium chloride, 2.7 mM potassium chloride, 1.0 mM magnesium
chloride, 1.2 mM calcium chloride, 2.0 mM sodium phosphate at a pH of 7.4, Fisher
Scientific] was perfused continuously at 2.0 μl/min through the dialysis probe for the
duration of the procedure. Baseline samples were collected at 20-min intervals for 2
hours prior to drug administration. Following the baseline samples, rats were injected ip
with saline, SCH 23390, or eticlopride, matching the antagonist treatment during
sensitization. After the baseline period, d-amphetamine sulfate was injected using a
cumulative dosing procedure similar to that used by Schad et al. (1996). Over the next
four 20 minute intervals, rats were given an injection of the following doses of damphetamine in this order: 0.1 mg/kg, 0.4 mg/kg, 1.0 mg/kg, and 1.5 mg/kg. This
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application results in a cumulative dose of 3.0 mg/kg of amphetamine by the end of the
drug administration. Samples were collected every 20 min throughout drug treatment
and 0.1 M perchloric acid was added to each vial to prevent catecholamine degradation.
Samples were stored at -80 degrees C for later analysis.
HPLC Analysis
In preparation for analysis, several concentrations of dopamine (DA), 3,4
dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and norepinephrine
(NE) were prepared in order to construct a standard curve from that the concentrations
of catecholamines could be calculated. Before analysis, samples were thawed.
Samples were injected into vials for analysis using an autosampler (ESA, Chelmsford,
MA). The autosampler injected 40 µl of each sample onto the detection column
allowing the sample to separate into its constituents that cleared the column at specific
retention times. The area of each target peak was compared to the standard curve to
calculate the concentration for each compound. The baseline concentrations of DA,
DOPAC, HVA, and NE were all calculated in picograms (pg) per 10 µl. For
microdialysis of all compounds following drug treatment, the percentage of baseline was
calculated based on the concentration of the target compound at each time point.
Statistical Analysis
Analysis of variance (ANOVA) was the primary statistical test with a Fischer‟s
post–hoc test used for statistical analysis of all significant interactions. The statistical
significance was set at p<0.05 for all analyses. In the research design, there were four
independent variables: neonatal drug treatment (between subjects, 2 levels: quinpirole
or saline); antagonist treatment (between subjects, 3 levels: SCH23390, eticlopride, or
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saline) adulthood drug treatment (between subjects, 2 levels: amphetamine or saline)
and sex (between subjects, 2 levels: male or female). Regarding microdialysis, the time
points were used as a repeated measure for the ANOVA analysis with regard to drug
treatment (neonatal, antagonist, and adult drug treatment) and expressed as a
percentage of baseline levels. Baseline levels were calculated by averaging the
dopamine overflow concentrations of the three samples from the last hour of baseline
collection. The drug treatment samples were then calculated as a percentage of the
baseline with each animal calculated independently. For this analysis, a 2 x 2 x 3 x 9
four-way ANOVA was initially used, with sex dropped as a variable when no sex
differences were found. Table 1 outlines the subject numbers and treatments for the
duration of the study.
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Table 1 Numbers and sexes of subjects and the treatment groups for treatment
throughout the study design. Neonatal treatments were given P1-11. The antagonist
treatments were administered during adulthood on behavioral testing days and on the
day of microdialysis.
Subjects
Neonatal treatment Antagonist treatment Adult drug treatment
8 Males, 8 Females

Saline

Saline

Saline

8 Males, 8 Females

Saline

Saline

Amphetamine

8 Males, 8 Females

Quinpirole

Saline

Saline

8 Males, 8 Females

Quinpirole

Saline

Amphetamine

8 Males, 8 Females

Saline

SCH23390

Saline

8 Males, 8 Females

Saline

SCH23390

Amphetamine

8 Males, 8 Females

Quinpirole

SCH23390

Saline

8 Males, 8 Females

Quinpirole

SCH23390

Amphetamine

8 Males, 8 Females

Saline

Eticlopride

Saline

8 Males, 8 Females

Saline

Eticlopride

Amphetamine

8 Males, 8 Females

Quinpirole

Eticlopride

Saline

8 Males, 8 Females

Quinpirole

Eticlopride

Amphetamine
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CHAPTER 3
RESULTS
Amphetamine Sensitization
Horizontal Activity
A repeated measures five-way ANOVA was used as the primary statistical
measure. There were a total of five factors in the experimental design: sex (2 levels:
male, female), neonatal drug treatment (2 levels: quinpirole, saline), antagonist
treatment (3 levels: saline, SCH23390, eticlopride), adult drug treatment (2 levels:
amphetamine, saline), and day of testing (repeated measure: day 1, day 7). Subjects
were behaviorally tested for 7 days, but analysis included only days 1 and 7 to compare
the beginning and end of drug treatment. The analysis of the microdialysis experiments
revealed no sex differences and data were consolidated over the sex variable. Across
all behavioral analyses there were no significant effects of estrus cycle stage; therefore,
data analyses were collapsed across that variable. A 2 (sex) X 2 (neonatal drug
treatment) x 2 (adulthood drug testing) x 2 (day of testing) x 3 (antagonist treatment)
five-way ANOVA revealed significant main effects for antagonist treatment, F(1,143) =
121.21, p<0.001, adult drug treatment, F(1,143) = 35.19, p<0.001, and day of treatment,
F(1, 143) = 4.90, p<0.029. There were six significant two-way interactions: neonatal
drug treatment x day of testing, F(1,143) = 4.867, p<0.029, antagonist treatment x day
of testing, F(2, 143) = 10.65, p<0.001, adult drug treatment x day of testing, F(1, 143) =
4.39, p<0.001, neonatal drug treatment x antagonist treatment, F(2, 143) = 6.70,
p<0.002, neonatal drug treatment x adult drug treatment F(1, 143) = 12.63, p<0.001,
and antagonist treatment x adult drug treatment, F(2, 143) = 15.96, p<0.001. There
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were also two significant three-way interactions of neonatal drug treatment x antagonist
treatment x adult drug treatment, F(2, 143) = 3.10, p<0.048 and sex x neonatal
treatment x antagonist F(2,143) = 2.844, p<0.043. Table 2 indicates treatment codes
for analysis.

Table 2 Treatment codes and abbreviations for groups.
Neonatal treatment Antagonist
Treatment

Adult Drug
Treatment

Group
Abbreviation

Saline

Saline

Saline

SSS

Saline

Saline

Amphetamine

SSA

Quinpirole

Saline

Saline

QSS

Quinpirole

Saline

Amphetamine

QSA

Saline

Eticlopride

Saline

SES

Saline

Eticlopride

Amphetamine

SEA

Quinpirole

Eticlopride

Saline

QES

Quinpirole

Eticlopride

Amphetamine

QEA

Saline

SCH23390

Saline

S1S

Saline

SCH23390

Amphetamine

S1A

Quinpirole

SCH23390

Saline

Q1S

Quinpirole

SCH23390

Amphetamine

Q1A

Analysis of the significant three-way interaction of neonatal drug treatment x
antagonist treatment x adult drug treatment revealed that Group QSA demonstrate
higher levels of activity than all other groups across both days of analysis. This finding
demonstrates that neonatal quinpirole treatment produced a significant enhancement of
the horizontal activity response to amphetamine, and this was blocked by either SCH
23390 or eticlopride. Analysis of the significant three-way interaction of sex x neonatal
drug treatment x antagonist showed that SCH23390 and eticlopride were both effective
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at blocking amphetamine sensitization in males, but in females only SCH 23390 was
effective, as Group SSA and SEA were equivalent at days 1 and 7 and both of these
groups were significantly higher than controls (Group SSS), figures 2 and 3. Therefore,
it appears that males demonstrate an increased sensitivity to a D2-like antagonist as
compared to females. Of course, this conclusion should be treated with some caution
because only one dose of each antagonist was tested.
Analysis of the significant two-way interactions revealed that neonatal quinpirole
treatment produced a significant increase in horizontal activity on day 7 as compared to
day 1. SCH 23390 produced a significant decrease in activity compared to controls on
days 1 and 7, whereas eticlopride actually produced a significant increase in horizontal
activity compared to controls at days 1 and 7. Amphetamine produced a significant
increase in horizontal activity at day 7 as compared to day 1. SCH 23390 was more
effective at blocking the effects of neonatal quinpirole treatment than eticlopride, likely
due to eticlopride‟s blockade of inhibitory D2-like autoreceptors. Neonatal quinpirole
treatment enhanced the locomotor activity response to amphetamine compared to
animals given neonatal saline. Finally, SCH23390 was more effective at blocking the
effects of amphetamine compared to eticlopride, as expected, and this is supported by
past work (Vezina, 1996). Analysis of the significant main effects revealed that
SCH23390 reduced activity levels more effectively than eticlopride treatment and also
prevented amphetamine-induced sensitization, supporting previous literature (Vezina
1996). Finally analysis of the significant main effect of adulthood drug treatment
revealed that d-amphetamine significantly increased horizontal locomotor activity across
days of testing as compared to saline controls, as expected. In sum, it appears that the
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D1 antagonist SCH 23390 was effective at blocking amphetamine sensitization and
producing locomotor hypoactivity, whereas the D2-like receptor antagonist eticlopride
blocked amphetamine sensitization, but produced less locomotor hypoactivity in
females as compared to males, and did not produce hypoactivity compared to controls.
This was to be expected, as eticlopride blocks the inhibitory dopamine D2 autoreceptor
and therefore increases dopaminergic activity, that would be expected to produce an
increase in locomotor activity.
A) SCH23390 - males

* indicates a significant difference in the saline-saline-amphetamine group
** indicates a significant difference from all other groups in the response of the
quinpirole-saline-amphetamine group
Figure 2 A) Horizontal activity of male subjects treated with SCH23390.
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B) Eticlopride - males

* indicates a significant difference in the saline-saline-amphetamine group
** indicates a significant difference from all other groups in the response of the
quinpirole-saline-amphetamine group
Figure 2 B) Horizontal activity of male subjects treated with eticlopride. The QSA group
had significantly different activity levels than all other groups on both days 1 and 7.
SSA animals showed significantly higher activity levels than saline-treated control
animals. SCH23390 was effective at lowering activity levels in all treatment constructs
to below control levels. Data are presented as means of groups +/- SEM.
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A) SCH23390 - females

* indicates a group with a significant difference from control
** indicates a group with a significant difference from all other groups
Figure 3 A) Horizontal activity of female subjects treated with SCH23390.
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B) Eticlopride - females

* indicates a group with a significant difference from control
** indicates a group with a significant difference from all other groups
Figure 3 B) Horizontal activity of female subjects treated with eticlopride. SSA animals
demonstrated a significant increase in activity over control animals. SCH23390 treated
groups exhibited lower levels of horizontal activity compared to control animals. The
SES group showed significantly greater activity than control animals on both days 1 and
7, with levels similar to the SSA group. Data are presented as means of each group +/SEM.
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Turning Behavior
Results are shown in figures 4 (males) and 5 (females). For turning behavior, an
initial analysis revealed no directional differences, so total (clockwise and
counterclockwise) turns were summed and averaged for each group on days 1 and 7.
Turning is presented as a function of neonatal drug treatment, antagonist drug
treatment, adult drug treatment, and day of testing in Figure 3.

A 2 x 2 x 2 x 2 x 2 five-

way ANOVA revealed a significant main effect of antagonist drug treatment F(1,162) =
98.81, p<0.001, day of treatment F(1,126) = 9.637, p<0.002 and adult drug treatment
F(1,162) = 6.395, p<0.013, one significant three-way interaction of Day X Antagonist
Treatment X Adult Drug Treatment F(1,162) = 3.802, p<0.025, one significant four-way
interaction: Day X Sex X Neonatal Treatment x Antagonist Treatment F(1,162) = 3.915,
p<0.05, and a significant five-way interaction of Day of Treatment X Sex X Neonatal
Treatment X Antagonist Treatment X Adult Drug Treatment F(1,162) = 4.242, p<0.041.
Analysis of the significant five-way interaction demonstrated that females given neonatal
quinpirole, saline as antagonist treatment and amphetamine as adult drug treatment
demonstrated a significantly higher amount of turning behavior as compared to all other
groups on the 1st day of treatment (day 1). Both SCH23390 and eticlopride blocked
increases in turning behavior produced by amphetamine, and SCH23390 was more
effective at blocking increases in turning behavior produced by amphetamine as
compared to eticlopride, consistent with the horizontal activity results. Analysis of the
significant four-way interaction again revealed that females given neonatal quinpirole
treatment and saline as antagonist treatment demonstrated significantly higher amount
of turning behavior on day 1. Post hoc analysis of the significant three-way interaction
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revealed that animals given saline as antagonist treatment and amphetamine as adult
drug treatment demonstrated significantly higher levels of turning behavior on day 7
compared to all other groups. The significant main effects revealed that SCH23390
blocked the increase in turning behavior more so than eticlopride, although both
significantly reduced turning behavior as compared to saline treated control subjects,
and amphetamine significantly increased turning behavior. It appears that D2 priming
as is produced by neonatal quinpirole treatment enhanced amphetamine-induced
turning behavior, but this effect was blocked by either D1 or D2 antagonism.
A) Males SCH23390

* indicates a group with a significant difference from control
** indicates a group with a significant difference from all other groups

Figure 4 A) Turning behavior of male subjects treated with SCH23390.
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B) Males Eticlopride

* indicates a group with a significant difference from control
** indicates a group with a significant difference from all other groups

Figure 4 B) Turning behavior of male subjects treated with eticlopride. SSA animals
demonstrated a significant increase in turning over control animals. SCH23390 treated
groups exhibited lower levels of horizontal activity compared to control animals. The
QSA group showed significantly greater activity than all other groups on both days 1
and 7. Data are presented as the mean of each group +/- SEM.
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A) Female SCH23390

* indicates a group with a significant difference from control
** indicates a group with a significant difference from all other groups

Figure 5 A) Turning behavior of female subjects treated with SCH23390.
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B) Female Eticlopride

* indicates a group with a significant difference from control
** indicates a group with a significant difference from all other groups
Figure 5 B) Turning behavior of female subjects treated with eticlopride. SSA animals
demonstrated a significant increase in turning over control animals on Day 7.
SCH23390 treated groups exhibited lower levels of turning compared to control animals.
The QSA group showed significantly greater activity than all other groups on both days
1 and 7. Data are presented as group means +/- SEM.

Microdialysis
As with behavior, there were a total of five factors in the experimental design:
sex (male, female), neonatal drug treatment (2 levels: quinpirole, saline), antagonist
treatment (3 levels: saline, SCH23390, eticlopride), adult drug treatment (2 levels:
amphetamine, saline), and time point after drug administration (repeated measure: time
point after drug administration). Across all analyses regarding DA, DOPAC, HVA, and
NE, there were no significant sex differences revealed and data were collapsed across
that factor for analysis. Thus, a four-way repeated measures ANOVA was the primary
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statistical measure for analysis of dopamine levels in the nucleus accumbens core
Additionally, initial analysis also revealed no significant effect of estrus cycle stage, so
data were collapsed over that factor as well.

Dopamine Overflow
Dopamine overflow in the nucleus accumbens core is presented as a function of
adult drug treatment and antagonist drug treatment in figures 6 (SCH23390) and 7
(eticlopride).
A four-way repeated measures ANOVA revealed three significant main effects:
time point F(8,84) = 2.46, p<0.012, antagonist drug treatment F(2,84) = 9.41, p<0.001
and adult drug treatment F(1,84) = 6.24, p<0.014, as well as four significant two-way
interactions: neonatal drug treatment x antagonist drug treatment F(2,84) = 4.61,
p<0.013, neonatal drug treatment x adult drug treatment F(1,84) = 4.58, p<0.04,
antagonist drug treatment x adult drug treatment F(2,84) = 12.77, p<0.001, time point x
antagonist drug treatment F(8,84) = 2.77, p<0.001 and one significant three-way
interaction time point x antagonist drug treatment x adult drug treatment F(16,84) = 2.67
p<0.001. Post hoc analysis of the significant three-way interaction revealed that
amphetamine produced a significant increase in dopamine overflow in animals given
saline for antagonist drug treatment at the 20-180 min time points. Post hoc analyses of
the significant two-way interactions revealed that neonatal quinpirole treatment coupled
with saline treatment for the antagonist drug treatment significant increased dopamine
overflow; neonatal quinpirole treatment enhanced dopamine overflow in animals treated
with amphetamine; rats given saline during antagonist drug treatment coupled with
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amphetamine for adult drug treatment demonstrated a significant increase in dopamine
overflow, and saline during antagonist treatment produced a significant increase in
dopamine overflow at time points 20-180 min after drug treatment. Amphetamine
treatment resulted in a significant increase in dopamine overflow as expected. Neonatal
quinpirole treatment followed by adult d-amphetamine administration resulted in the
greatest increase in dopamine overflow (Nowak et al. 2001, Cope et al. 2008). Thus D2
priming appears to poteniate the increase in dopamine overflow seen following adult
amphetamine administration. It appears that both SCH23390 and eticlopride can
effectively attenuate the D2 priming effect that results in increased dopamine overflow in
the nucleus accumbens. This may be the result of a lack of D1/D2 synergism in the
presence of antagonism of either the D1 or D2 receptor.

Figure 6 Dopamine overflow in subjects treated with SCH23390. Group QSA exhibited
significantly higher levels of dopamine in samples than all other groups. Group SSA
also exhibited increased dopamine levels compared to antagonist treated subjects. A
single * represents a significant difference from saline-treated control subjects (SSS). **
represent a significant difference from all other groups. Arrows indicate cumulative
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dosing of amphetamine as the experiment progressed. Values are means for each
group +/- SEM.

Figure 7 Dopamine overflow in subjects treated with eticlopride. Eticlopride treated
subjects demonstrated no significant difference in dopamine levels compared to control
subjects. A single * represents a significant difference from control subjects.
** represent a significant difference from all other groups. Arrows indicate cumulative
dosing of amphetamine as the experiment progressed. Values are means for each
group +/- SEM.

DOPAC Overflow
A four-way repeated measures ANOVA revealed two significant main effects:
time point F(8,96) = 2.41, p<0.014, adult drug treatment F(1,96) = 5.75, p<0.018, and
one significant three-way interaction neonatal drug treatment x antagonist drug
treatment x adult drug treatment F(2,96) = 3.79, p<0.026. Post-hoc analysis of the
significant three-way interaction revealed that neonatal quinpirole treatment coupled
with SCH-23390 and amphetamine treatment in adulthood produced a significant
increase in DOPAC overflow, data represented in table 3. Neonatal quinpirole
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treatment resulted in an increase in DOPAC, and SCH 23390 was unable to reduce
DOPAC overflow to control levels. Taken together, these results indicate that D2
priming facilitates DOPAC overflow. No other significant differences were found
between groups. Analysis of the significant main effects revealed that there were
significant changes in DOPAC over the different time points, and amphetamine
significantly increased DOPAC compared to rats treated with saline.

Table 3 DOPAC Microdialysis. DOPAC results from microdialysis presented as an
average concentration for each group following adult drug treatment (AMPH or saline).
Values are DOPAC concentrations in picograms. A * denotes a significant difference
from saline-treated control animals (SSS).

Group
Mean
Abbreviation Concentration
Q1A
128.09*
Q1S
96.54
QEA
90.22
QES
145.56*
QSA
81.66
QSS
321.53
S1A
80.79
S1S
113.34
SEA
89.12
SES
135.92
SSA
80.02
SSS
87.18
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Norepinephrine Overflow
A four-way repeated measures ANOVA revealed a significant main effect of time
point F(8,80) = 2.20, p<0.026, three significant two-way interactions: time point x
neonatal treatment F(1,80) = 5.37, p<0.023, time point x antagonist treatment F(2,80) =
6.83, p<0.002, time point x adult drug treatment F(1,80) = 8.35, p<0.005 and a
significant four-way interaction of time point x neonatal treatment x antagonist treatment
x adult drug treatment F(2,80) = 3.53, p<0.034. Post hoc analysis of the significant fourway interaction revealed that rats given neonatal quinpirole treatment, saline as their
antagonist drug treatment, and amphetamine in adulthood produced a significant
increase in NE overflow at 80, 100, and 120 min post drug treatment, data shown in
figures 10 and 11. Interestingly, saline-treated controls demonstrated significantly
greater levels of norepinephrine at the 20 and 40 minute time points following drug
administration, but this may also been due to unstable baseline in this group (data not
shown). Overall, amphetamine treatment without antagonism produced a significant
200% increase in NE levels at 80, 100, and 120 minutes post drug treatment in the
nucleus accumbens core compared to controls, consistent with previous work
(McKittrick and Abercrombie 2007). Antagonist treatment with either SCH23390 or
eticlopride blocked the effects of amphetamine on NE with levels equal to saline treated
controls (Group SSS).
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Figure 8 Norepinephrine overflow in subjects treated with SCH23390. All groups
demonstrated significantly lower levels of norepinephrine for the first 60 minutes post
drug as compared to saline-treated control subjects. At 100 minutes post drug
treatment, groups SSA, QSA and QSS exhibited higher levels of norepinephrine than
saline-treated control subjects. Arrows represent dosage of amphetamine in mg/kg
administered at each time point. Data are represented by percentage of baseline +/SEM. A * represents a significant difference from saline-treated control subjects (SSS).
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Figure 9 Norepinephrine overflow in subjects treated with eticlopride. Groups SSA and
QSA exhibited significantly higher levels of norepinephrine compared to control
subjects. Group QEA exhibited significantly higher levels of norepinephrine compared
to control groups. No other significant differences were found. Arrows represent
dosage of amphetamine in mg/kg administered at each time point. Data are represented
by percentage of baseline +/- SEM. A * represents a significant difference from salinetreated control subjects (SSS).

Homovanillic Acid Overflow
A 2 x 2 x 3 x 9 revealed no main effects or interactions of drug treatment in the
levels of homovanillic acid (HVA) during baseline or after drug treatment.
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CHAPTER 4
DISCUSSION

The results of this study indicate several important findings. First, neonatal
treatment with the D2/D3 receptor agonist quinpirole enhanced sensitization to
amphetamine in adulthood. Second, neonatal quinpnirole treatment also enhanced the
dopaminergic response to amphetamine in adulthood in the nucleus accumbens core.
Third, it appears that both the D1 and D2 receptors are differentially involved in
amphetamine-induced sensitization. Based on findings that D2 primed animals
exhibited an increased locomotor response and dopamine overflow in a brain area
associated with drug reward, this study indicates that enhancing dopamine D2 receptor
sensitivity enhances the behavioral and dopaminergic response to amphetamine, that
presumably increases the rewarding effect of the drug in D2 primed animals. This is
consistent with previous studies that have shown neonatal quinpirole treatment
produces a more robust sensitization to the psychostimulant nicotine in adolescence
and adulthood and produces a more robust dopaminergic response to amphetamine in
adulthood, that is consistent with the effects reported here, because both amphetamine
and nicotine are in the psychostimulant drug family (Perna et al. 2008, Cope et al.
2009).
In terms of the roles of D1 and D2 receptors, although both D1 and D2
antagonism blocked amphetamine sensitization in males and dopamine overflow,
pretreatment with the D1 receptor antagonist SCH-23390 was more effective in
producing a reduction in locomotor activity in males and dopamine overflow than the
D2-like receptor antagonist eticlopride. Pre-amphetamine treatment with the D1
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antagonist SCH 23390 blocked both locomotor sensitization to amphetamine as well as
accumbal dopamine overflow, consistent with our hypothesis. Previous work has shown
that D1 receptors are necessary for the induction of behavioral sensitization (Vezina
1996). Results here confirm that the blockade of the D1 receptor with SCH23390 is
sufficient to prevent amphetamine-induced behavioral sensitization. It has been
postulated that induction of enduring enhancements in the ventral tegmental area (VTA)
induced by amphetamine involve the somatodendritic release of dopamine and its
action at dopamine D1 receptors. Dopamine D1 receptors in the VTA appear to be
positioned such that they can exert a critical influence on the initiation of changes in the
reactivity of accumbal dopaminergic neurons that lead to a long-term sensitized
locomotor response as well as dopaminergic response from the nucleus accumbens
(Vezina 1996). The release of both GABA and glutamate into the ventral tegmental
area has also been shown to be modulated by D1 receptors (Cameron and Williams
1993, Kalivas and Duffy 1995), and both of these neurotransmitters have been shown to
influence the induction of behavioral sensitization to psychostimulants (Wolf et al. 1994).
Thus, the induction of sensitization may depend on D1 mediated release of
neurotransmitters in addition to dopamine. The drug reward pathway including the
ventral tegmental area and nucleus accumbens are represented in figure 10.
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The box denotes the
brain region
containing the reward
circuitry. The lines
within the box
represent the
mesolimbic pathway.
Nucleus
Accumbens

Ventral
Tegmental
Area

Figure 10 Schematic of the reward pathway involved in addiction. Figure modified from
NIDA Notes, 1996.

The inhibitory action of dopamine has been shown to be enhanced in
psychostimulant-sensitized animals and that this effect is also mediated by D1-like
receptors (O'Donnell and Grace 1994). For example, GBR12909, a dopamine transport
(DAT) inhibitor, showed no effect on the synaptic action of dopamine following
psychostimulant treatment indicating that the enhancement of the presynaptic inhibition
is not likely to be attributed to downregulation of dopamine transporter activity (Beurrier
and Malenka 2002). Rather, this change in presynaptic inhibition appears to be caused
by a modification of the number of presynaptic D1-like receptors. Past results have
shown, for instance, that chronic administration of the dopamine reuptake inhibitor
cocaine results in increased inhibitory action of D1 agonists on single-unit responses of
nucleus accumbens neurons (Henry and White 1991). These data suggest that the
effect of D1 receptors in behavioral sensitization are the result of increased postsynaptic
inhibition. This theory is supported by the decreased locomotor response and of
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dopamine overflow following treatment with the D1 receptor antagonist SCH23390. The
reduction of dopaminergic overflow in this study produced by SCH 23390 was not
accompanied by a comparable increase in the dopamine metabolites DOPAC or HVA,
indicating that the change occurs outside of the metabolism of dopamine and supports a
change in the receptor functionality.
Although Vezina postulated that induction of behavioral sensitization requires the
D1 but not the D2 receptor (1996), results here indicate a role of the D2 receptor in
behavioral sensitization. However, this may be the result of differences in design and
methodology. Vezina (1996) employed a pretreatment of SCH23390 for D1 antagonism
or eticlopride, spiprerone or sulpiride for D2 antagonism followed by amphetamine or
saline treatment up to 1 hour later, and sensitization was tested by amphetamine
challenge 1-3 weeks later. In the present study, antagonist administration was followed
by amphetamine administration by only 10 mins, that could be related the time course
and action of eticlopride and its efficacy to block not only D2 subtypes but D3 receptor
subtypes. Additionally, in the present study amphetamine was administered every other
day for a total of seven exposures. In the Vezina (1996) study, amphetamine was
administered at a dose of 1.0 mg/kg once every 3rd day for five injections. Though the
doses of amphetamine, eticlopride, and SCH23390 were the same in both studies, it is
likely that the differences in experimental design may account for the differences in
effects at the D2-like receptors in these studies. It is not possible to exclude a possible
impact of the D3 receptor since both quinpirole and eticlopride have possible effects at
the D3 receptor in addition to the D2 receptors within this study. Vezina (1996)
suggested that D2 receptors did not have a role in sensitization to amphetamine and
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showed similar results using three dopamine D2 antagonists, two of that are more
selective to the D2 receptor than eticlopride. Interestingly, eticlopride treatment to rats
neonatally treated with saline resulted in locomotor activity levels that were similar to
non D2-primed animals treated with amphetamine as seen in figures 2b and 3b.
Dopamine D2-primed animals receiving eticlopride and amphetamine resulted in a
locomotor profile very similar to that of non D2-primed subjects receiving eticlopride
alone. Such findings suggest that systemic eticlopride can attenuate the locomotor
effects of amphetamine, but that eticlopride treatment alone given in adulthood creates
a change in dopamine receptors that results in behavioral changes similar to those seen
from neonatal priming. Interestingly, past studies have shown that eticlopride (0.6
mg/kg) potentiates dopamine release by amphetamine using functional MRI as well as
in locomotor activity (Tanabe et al. 2004; Chen YC et al. 2005), although in the latter
study, eticlopride was infused into the VTA. There is no doubt that differences in
administration routes (i.e. intrabrain administration versus systemic ip injection) and
dosages may account for differential results, and, in fact, it suggests that the effects of
systemic administration of eticlopride on dopamine overflow is fundamentally different
from direct infuction into brain areas.
Interestingly, there were sex differences in the response to eticlopride. Pretreatment with eticlopride blocked sensitization to amphetamine more effectively in
females than in males but completely blocked amphetamine‟s effects on accumbal
dopamine overflow equally across both sexes. This is inconsistent with our hypothesis
but poses an interesting finding in that this is the only study to analyze the effects of
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systemic treatment with the D2/D3 antagonist eticlopride on amphetamine sensitization
and its effects on dopamine overflow.
Amphetamine administration significantly increased turning behavior in males
and females, an effect that was blocked by both D1 and D2 antagonist treatment,
though D1 blockade was more effective, similar to results with horizontal activity. This
behavioral effect also may be the result of a greater density of striatal dopamine D1
receptors and turning behavior has been shown to be a valid test of striatal function.
Amphetamine action on neurotransmission is complex. First, amphetamine
uptake by DAT is required. Second, amphetamine then inhibits the activity of vesicular
monoamine transporter (VMAT) resulting in an increase in non-vesicular cytosolic
neurotransmitter concentrations. This increase in neurotransmitter results in reverse
transport of the neurotransmitter via membrane-bound transporters (Sulzer et al. 1993;
Sulzer et al. 1995). Quantification of neurotransmitters by microdialysis following
amphetamine administration is a result of overflow rather than vesicular release of the
neurotransmitter. Results showed amphetamine-induced overflow of dopamine in the
nucleus accumbens (core) in rats was greater in rodents repeatedly treated with
quinpirole during the postnatal development period (Nowak et al. 2001).
It is hypothesized that the underlying mechanism of this effect is related to
several factors. First, amphetamine produced a significant increase in dopamine
overflow. Second, amphetamine has been shown to produce a subsensitization of
presynaptic D2 autoreceptors in the VTA. Third, neonatal quinpirole produces
supersensitization of postsynaptic D2 receptors resulting in an increased dopaminergic
response to amphetamine (Nowak et al. 2001). This increased dopaminergic response
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presumably results in a more robust behavioral activation to the drug. There is another
complex caveat to this mechanism. Based on the fact that quinpirole is a D2/D3 agonist,
it binds to and activates both the presynaptic inhibitory D2 autoreceptor as well as the
postsynaptic D2 receptor. Past work has shown that acute quinpirole treatment actually
produces a decrease in dopamine overflow (Nowak et al. 2001) in the dorsal striatum,
and this is presumably due to its action at the autoreceptor. Therefore, it is assumed
that quinpirole primes both the D2 inhibitory autoreceptor and the D2 postsynaptic
receptor with roughly equal affinities. A critical action relative to the results observed
here is that amphetamine produces subsensitivity of the inhibitory D2 autoreceptor.
Therefore, supersensitization of the postsynaptic receptor as is produced by neonatal
quinpirole is the most plausible explanation of the mechanism observed in the present
study.
The mechanism of D2 receptor supersensitivity, or D2 priming, is unknown.
When D2 receptors are activated, a G-protein coupled receptor (GPCR), like the
dopamine-bound D2 dopamine receptor, binds a trimeric G-protein and catalyzes the
exchange of GTP for GDP at the alpha subunit of the G-protein that leads to the
dissociation of GTP bound alpha subunit. This dissociation allows the freed dimer to
regulate activity of cellular effector molecules. Signal termination is mediated by the
GTPase activity intrinsic to the alpha subunit. The GTPase hydrolyzes the bound GTP
to GDP allowing the subunit to reassociate with the dimer (Ross and Wilkie 2000).
GTPase activity of the alpha subunit and thereby the signal termination of the GPCR
can be enhanced by members of a family of proteins called regulators of G-protein
signaling (RGSs) (Berman and Gilman 1998, Ross and Wilkie 2000). One such protein,
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RGS9, has a splice transcript RGS9-2 that is confined to the striatum (Thomas et al.
1998). Mice with a null mutation in the RGS9 gene showed heightened locomotor
responses to cocaine and related psychostimulants, whereas viral-mediated
overexpression of RGS9-2, but not RGS4, in rat striatum specifically reduced locomotor
responses to D2 receptor agonists (Rahman et al. 2003). As mentioned above in the
introduction, we have shown that RGS9 is significantly downregulated in D2 primed
animals as compared to non D2-primed animals (Maple et al. 2007) in several heavily
innervated dopaminergic brain areas, including the striatum, nucleus accumbens, and
frontal cortex. Therefore, it appears that regulation of D2 receptor signal transduction is
lessened in animals neonatally treated with quinpirole, likely resulting in an overall
increased response from this family of receptors. Modifications of downstream proteins
including, but not limited to, the RGS family of proteins may help to account for the
modifications of the cascade resulting in greater or prolonged dopaminergic effect
following amphetamine administration. However, it should be noted that no second
messenger system has been identified to fully account for the supersensitization
following neonatal quinpirole treatment.
Amphetamine has been shown to produce an additive effect on extraneuronal
dopamine levels in both the striatum and nucleus accumbens core in rats neonatally
treated with quinpirole (Nowak et al. 2001, Cope et al. 2009). This additive effect may
result from amphetamine actions mediated by both the D1 and D2 receptors. In this
study we attempted to elucidate the roles of each receptor. Results here suggest the
D1 receptor does play a role in regulating the extraneuronal levels of dopamine in the
nucleus accumbens core. However, eticlopride blockade of the D2 receptor also
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attenuates the effects of amphetamine on extraneuronal dopamine in the nucleus
accumbens. Such an impact of singular receptor blockade implicates mediation by
synergistic effects of the D1 and D2 receptors. It has been shown that concomitant
stimulation of the D1 and D2 receptors is required under normal conditions for many
actions of dopamine, a phenomenon referred to as D1/D2 synergism (Gershanik et al.
1983, La Hoste et al. 1996). This type of receptor interaction is representative of an
extreme form of synergism in that the effect of two combined drugs exceeds the
algebraic sum of their two effects. In this form, two drugs (e.g. D1 and D2 agonists)
potentiate the effects of the other and each is ineffective without the other based on the
activation of both dopamine receptor subtypes. It is the concurrent activation of both
receptor subtypes that results in the synergistic effects. In terms of amphetamine, an
indirect dopamine agonist, administration results in an increased dopamine release
resulting in stimulation of D1 and D2 receptors postsynaptically, an idea supported in
work showing that blockade of presynaptic autoreceptors does not impact this D1 and
D2 interaction (Shi et al. 1997).
Synergism is evident in the control of motor behavior. For example, reserpineinduced akinesia can be reversed by combined but not separate administration of a
selective D1 or selective D2 agonist. Increases in locomotion and motor stereotypy
elicited by the indirect dopamine agonists apomorphine and amphetamine can be
blocked by either a selective D1 or D2 antagonist (Lewis et al. 1983, Martres et al.
1992). The results of this study provide further evidence that there is such interplay
between dopamine receptors given the ability of either D1 or D2 antagonist treatment to
prevent amphetamine-induced increases in locomotion. It must be noted that basal
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levels of endogenous dopamine may provide sufficient D1 tone to synergize with an
exogenous D2 agonist. Administration of a D1 agonist alone does not elicit motor
stereotypy, whereas administration of a D2 agonist alone does (White et al. 1988).
Following selective destruction of central dopaminergic neurons with the
neurotoxin, 6-hydroxy-dopamine (6-OHDA), or prolonged depletion of monoamines with
reserpine, there is a increased expression of striatal D2 receptors and animals become
supersensitive to D1 or D2 agonists (La Hoste et al. 1993a). Accompanying the agonist
supersensitivity is a complete breakdown of requisite D1/D2 synergism. Functions that
previously required concomitant D1/D2 stimulation can be mediated by independent
stimulation of either D1 or D2 receptors. This is true for stereotyped motor behavior,
inhibition of striatal neuron firing, and striatal c-fos expression (La Hoste et al. 1993b).
D1/D2 synergism may then play a role in amphetamine induced behavioral sensitization
but does not account for effects following D2 receptor priming as it is expected that such
priming would break down the synergistic mechanism. A breakdown in D1/D2
synergism as a result of priming is thought to be the result of a lack c-fos expression in
the striatum following D2 agonist treatment. The absence of c-fos causes a change in
the downstream cascade of gene expression that persists for at least 8 hours, a time
consistent with that of causal events leading to increased sensitivity and a breakdown in
D1/D2 synergism (LaHoste et al. 1993b).
Functional modifications of dopamine receptors have been implicated to be
critical in the process of sensitization with regard to psychostimulants including
amphetamine, nicotine, and cocaine (Kalivas and Duffy 1993; Kalivas et al. 1993;
Vanderschuren and Kalivas 2000). Such a functional change has been specified to
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exist in the mesocorticolimbic pathway, the pathway implicated in behavioral
sensitization (Kalivas et al. 1993).
Both dopamine D1 and D2-like receptors in the NAcc as well as glutamate
NMDA and AMPA receptors located on medium spiny neurons in the VTA are primary
targets for altered neurotransmission following amphetamine or cocaine treatment
(Montague et al. 2004, Hyman et al. 2006). When animals are sensitized to a drug,
prior research suggests, dopamine D1 receptor supersensitivity occurs in the nucleus
accumbens as a result of the upregulation of the cAMP pathway (Nestler and
Aghajanian 1997). The blockade of dopamine D1 receptors in the present study
prevented amphetamine-induced sensitization, an effect that may be explained by
changes in the cAMP pathway. This cellular event may impact downstream G-protein
coupling and result in an upgregulation of adenylyl cyclase and protein kinase A signals.
D1 dopamine receptor-mediated cellular signaling cascade could then enhance the
phosphorylation of the transcription factor cAMP response element binding protein
(CREB) and the expression of immediate-early genes, such as Fos and Jun (Nestler
2002, Waters et al. 2003). Induction of expression of those genes is rapid and mostly
transient and invokes subsequent gene expression (Zhang et al. 2005). For example,
activation of CREB by phosphorylation is a common neuronal adaptation in the nucleus
accumbens to psychostimulants (Impey et al. 2004). Previous studies suggest that
drug-induced CREB activation/phosphorylation in the nucleus accumbens constitutes a
negative feedback mechanism that dampens behavioral sensitivity to subsequent drug
exposure (Carlezon et al. 2005).
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Further, the accumulation of ΔFosB in the nucleus accumbens is a universal
phenomenon following chronic exposure to abused drugs (Nestler et al. 1995). Over
expression of ΔFosB in the nucleus accumbens increases the behavioral response to
cocaine and amphetamine and the amount of ΔFosB accumulation in the nucleus
determines the duration and intensity of drug-induced behavioral sensitization (McClung
et al. 2004). Blockade of the D1 receptor with SCH23390 has been shown to attenuate
the induction of fos proteins but D2 receptor antagonist treatment increased fos related
proteins levels seen following amphetamine treatment (Nestler et al. 1995). In terms of
the molecular mechanism underlying dopaminergic receptor involvement in behavioral
sensitization, fos proteins, including ΔFosB, appear to play a larger role in changing the
downstream gene expression following drug exposure. Results involving the fos
proteins appear to indicate that the D1 receptor plays the mediating role in sensitization.
Thus, modulation of dopamine receptors through antagonism may reduce the
amphetamine-induced increases ΔFosB, allowing for a potential modulation of
behavioral sensitization. A future study in this laboratory will analyze the expression of
delta FosB within this model.
The results of this study support the theory that both D1 and D2 receptors have
a role in amphetamine behavioral sensitization. Further, D2 primed animals appear to
have an increased sensitivity at the D2 receptor such that the coupled treatment of
quinpirole and eticlopride results in a stimulated response comparable to animals
treated with amphetamine regardless of neonatal drug treatment. This may support the
idea that D2 priming produces an autoreceptor subsenstivity that enhanced the
dopaminergic response similar to that of amphetamine (Kostrzewa et al. 2008). As
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expected, dopamine D1 antagonist treatment in D2-primed animals was more effective
in reducing locomotor activity in female rats than male rats compared to saline treated
control subjects because female rats are more susceptible to antagonist effects than
males (Schindler and Carmona 2002). This supports previous work showing that
females are more susceptible to the effects of dopamine D1 receptor blockade than are
males, although D2 blockade using eticlopride has been shown to be effective at
blocking cocaine sensitization in at least one past study (Schindler and Carmona 2002),
whereas in the present study eticlopride was not effective at blocking amphetamine
sensitization in adult females. This points to a possible sexual dimorphism not only in
the response to antagonists but in the combination of dopaminergic antagonists with
amphetamine.
With regard to D2 receptors, increased antagonist susceptibility may arise from
dopaminergic fluctuations related to estrogen levels and stages of the estrus cycle. In
females, estrogen acts to inhibit GABA neurons in the striatum and accumbens resulting
in increased dopamine function. Estrogen also acts to enhance dopamine release by
downregulating D2 receptor function (Becker 1999). Though no effects of estrus cycle
stage were found associated with sex differences in locomotor activity in the present
study, that may be the result of insufficient sample size in each stage of estrus.
However, animals were treated every other day for the duration of sensitization;
therefore, female subjects should have been administered adult drug treatment and
antagonist across all stages of the cycle.
D2 primed animals treated with eticlopride exhibited no difference relative to
saline treated controls on the horizontal activity measure. However, non D2-primed
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females treated with eticlopride and saline exhibited an increase in locomotor activity as
compared to saline- treated control subjects. This is likely the result of presynaptic
autoreceptor blockade that results in a disinhibition of dopamine release, thereby
stimulating additional dopamine release and increasing locomotor activity (Goldwert et
al. 2006). Female rats showed a greater reduction in activity following SCH23390
treatment as compared to males, consistent with past work (Schindler and Carmona
2002). This difference in D1 response may also be the result of dopaminergic changes
associated with estrogen (Becker 1999). However, the nucleus accumbens plays a
significant role in behavioral sensitization and males show a higher density of D1
receptors in the nucleus accumbens (Andersen et al. 1997). This difference in receptor
density may also account for an increased impact in females. Less dense populations
of receptors would likely result in a greater occupancy of receptors by a lower dose of
antagonist and may account for females responding in a more significant way to
receptor blockade. As expected, males showed a less robust sensitization response to
amphetamine compared to females. This expectation was based on previous work that
has shown that the D1 receptor plays a more important role in amphetamine
sensitization, although there are no data on sex differences in the roles of D1 and D2
receptors in amphetamine sensitization.
In terms of behavioral sensitization, past work has shown that females exhibit
more robust sensitization than do intact males to amphetamine (Camp and Robinson
1988, Becker 1999, Perna et al. 2007, Cope et al. 2008). We hypothesized that female
rats would be more sensitive to the antagonism treatments of both D1 and D2
receptors. One of the more important and interesting effects reported here was that
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blockade of the D1 receptor completely blocked sensitization to amphetamine in both
males and females, at least implying D1 receptor function is similar across the two
sexes in terms of amphetamine sensitization. In contrast, blockade of the D2 receptor
by eticlopride was more effective at blocking amphetamine sensitization in males as
compared to females, suggesting a sex difference in D2 function. One issue here is that
eticlopride is only 3-4 fold more selective for the D2 receptor subtype as compared to
the D3 receptor subtype (Claytor et al. 2006). Thus, this may be reflective of sex
differences of not only the D2 but D3 receptor subtype of the D2 receptor family. A more
selective D2 receptor antagonist may be able to more effectively ascertain the roles of
the D2 and D3 receptors in males and females. In other work from this lab, both D2 and
D3 receptor subtypes have been shown to be involved in the locomotor activating
effects of nicotine (Sheppard 2008). A second issue here, however, is that sex
differences in D2 receptor function have been shown. Females demonstrate a higher
amount of locomotor activation when D2 receptors are activated by an agonist
(Szumnlinski et al. 2000, Schindler & Carmona, 2002) but locomotor depression to D2
antagonism, although this study used adolescents (Sheppard et al. in press).
Additionally, age differences in the development of dopamine receptors prevalent in the
striatum and nucleus accumbens have been shown (Andersen & Teicher, 2000).
Females demonstrate a more stable number of D2 receptors throughout development,
whereas males exhibit a lower amount of D2 receptors in early adolescence with the
number peaking in mid-adolescence before being reduced to equivalent numbers of D2
receptors as females in adulthood. This may have repercussions as to the adult
dopamine function as well, but this has yet to be delineated. Regardless, these results
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support past work that sex differences in D2 function and D2 receptor development
exist.
There are no results from DOPAC or HVA samples that indicate increased
dopaminergic overflow is the result of a change in dopamine metabolism. D2-primed
animals treated with saline as well as primed animals treated with SCH23390 and
amphetamine revealed a significantly higher level of DOPAC in microdialysate samples
as compared to saline treated controls. These results suggest that the D2 priming
related increase in DOPAC is not related to D1/D2 synergism, as said increase can not
be fully attenuated following D1 receptor blockade. Additionally, at 40 minutes post
drug treatment, non-D2-primed animals treated with SCH23390 show elevations in
DOPAC release. This may indicate an increase in dopamine catabolism that resolves
at 60 minutes potentially indicating a freeing up of previously bound receptors or a selfresolving mechanism following dopamine catabolism. This follows the results that
SCH23390 can increase dopamine overflow due to its action on presynaptically located
D1 receptors (Egilmez et al. 1995). Thus, it is then likely that changes occur within
presynaptic receptor functionality rather than dopamine metabolism following release.
Maybe the most important aspect of the present study is that these results are
consistent with clinical findings. Schizophrenic patients, using a single photon emission
computerized tomography (SPECT), have shown increased striatal dopamine release in
response to an amphetamine challenge as compared to healthy matched control
subjects (Laruelle et al. 1996, Abi-Dargham et al. 1998). Increased dopaminergic
transmission was also associated with behavioral consequences (e.g. worsening or
emergence of psychotic symptoms). The effects of amphetamine on subjects were not
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attributable to peripheral effects of the drug. More specifically, increased striatal
dopamine release following amphetamine administration is associated with the D2
receptor sensitivity (Laruelle et al. 1996, Abi-Dargham et al. 1998). These studies
present a clinical correlation for the findings of this study in terms of increased
dopaminergic overflow and locomotor findings. Taken together, these results confirm
the involvement of the dopamine D2 receptor in terms of modeling psychosis, and more
specifically, schizophrenia.
In the current study, amphetamine was shown to significantly increase
norepinephrine overflow in both D2-primed and non D2-primed male and female rats,
although neonatal quinpirole treatment did not enhance this effect. This result is
consistent with work by McKittrick and Abercrombie (2007) who have shown systemic
amphetamine administration resulted in a significant increase in norepinephrine
overflow in the nucleus accumbens. Treatment with either D1 or D2 antagonist blocked
the amphetamine-induced increase in norepinephrine overflow in the nucleus
accumbens.
It has been shown that norepinephrine overflow in the rat nucleus accumbens is
under the opposing influence of stimulatory dopamine D1 and inhibitory dopamine D2
receptors (Vanderschuren et al. 1999). The D2 antagonist sulpiride has been shown to
strongly increase norepinephrine overflow in the nucleus accumbens, whereas the D1
antagonist SCH23390 did not reduce norepinephrine overflow (Vanderschuren et al.
1999). Results of this study similarly show that SCH23390 does not significantly reduce
norepinephrine as compared to control subjects; however, the D2-like antagonist
eticlopride does not appear to increase norepinephrine overflow. Inhibitory dopamine
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D2 receptors have been shown to regulate norepinephrine overflow, as opposed to the
enhancing effects of the dopamine D1 receptor in an in vitro study using superfusion
techniques (Vanderschuren et al. 1999). Results here support that idea as eticlopride
as a D2 like antagonist blocked norepinephrine overflow in the nucleus accumbens. It
is important to note that effects of eticlopride may not be limited to the D2 receptor, as
eticlopride also has significant affinity for the D3 receptor. The limitations of this study
do not allow a complete understanding of any potential involvement at D3 receptors.
The combined treatment of quinpirole and amphetamine result in an increased
norepinephrine overflow at the 80, 100, and 120 minute time points. If released
endogenous dopamine tonically inhibits norepinephrine overflow in the nucleus
accumbens through the stimulation of D2 receptors, then D2 primed animals, as well as
non D2-primed animals treated with amphetamine should have similar norepinephrine
levels to saline controls an idea supported by the data. Dopamine D2 receptors are
located near active zones formed by dopamine and norepinephrine terminals, whereas
dopamine D1 receptors are located more distally from the site for dopamine overflow
(Sesack et al. 1994, Hersche et al. 1995). It may be that dopamine released from
mesolimbic neurons preferentially interacts with D2 receptors located closer to the
terminal of release (Vandershuren 1999). If such a proximal relationship prevails,
blockade of the D2 receptor by eticlopride would then inhibit norepinephrine overflow in
the nucleus accumbens. Dopamine D2-primed animals treated with amphetamine as a
result of the increased dopamine overflow would activate both D1 and D2 receptors
resulting in a net increase in norepinephrine overflow. Dopamine D2 receptor priming

85

alone would not be expected to enhance norepinephrine overflow but rather to inhibit
such overflow.
Conclusions
Dopaminergic dysfunction is implicated in underlying several mental illnesses
including schizophrenia, obsessive-compulsive disorder, and bipolar disorder. Mental
illnesses are often comorbid with substance abuse disorder leading to a dual diagnosis.
Such a dual diagnosis complicates treatment and may impact the overall effectiveness
of pharmacological interventions. Using a D2 priming model to mimic dopamine D2
receptor dysfunction in mental illness, changes in receptor sensitivity result in changes
in amphetamine-induced locomotor response and dopamine overflow in the nucleus
accumbens. Results of this study are that D2 priming enhanced the dopaminergic
response to amphetamine in adulthood, an effect alleviated by blockade of either D1 or
D2 receptors. Second, changes in D2 receptor sensitivity may increase the positive
reinforcing effect of a psychostimulant drug in adult animals. Third, D1 receptor
blockade was more effective in reducing locomotor activity in males and dopamine
overflow than D2 receptor blockade b eticlopride. Fourth, females are more sensitive to
the effects of D1 receptor blockade than males.
If supersensitization is a key aspect of psychosis, these changes may represent
a mechanism toward the increased abuse of drugs in humans suffering from these
psychotic disorders. Blockade of dopamine D2 receptors results in patterns of
locomotor activity and dopaminergic overflow similar to that seen from amphetamine
administration, likely a result of presynaptic autoreceptor inhibition. Dopamine D1 and
D2 receptors differentially play a role in amphetamine-induced sensitization. Dopamine
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D1 receptor blockade is more effective at preventing locomotor sensitization than D2
receptor blockade. This may indicate a primarily motor involvement of the D1 receptor
family in terms of behavioral sensitization rather than involvement in the rewarding
properties of amphetamine. Conversely, dopamine D2 receptor may play less of a role
in the activating effects of amphetamine, but when antagonist to this receptor are given
systemically, they appear to produce a different effect on dopamine function than when
infused. Precisely the mechanism behind this is not known and outside of the scope of
the present work but opens up an interesting area of research. All antipsychotic drugs
antagonize the D2 receptor (Tollefson 1996) and are obviously given systemically.
Thus, it appears that the route in that this drug is given may have important implications
relative to its effects on neurochemistry and specifically, dopamine function.
It is unclear what impact sex differences have in this interaction. Females were
more susceptible to the effects of dopamine antagonists than males. Further
experimentation is required to clearly elucidate sex differences in D2 primed animals
and how this may be related to hormonal fluctuations. Clinical results have shown that
female patients are more sensitive to the effects of abused drugs (Carroll et al. 2004), a
result supported here. Many such measurements of response to a drug in a clinical
setting are subjective and cannot be modeled in animals. Animal models are then
limited in allowing a full understanding of underlying sex differences in a dual diagnosis.
Dopaminergic dysfunction may underlie mental illnesses and increases in dopamine D2
sensitivity may represent a mechanism for vulnerability to psychostimulant abuse,
particularly in terms of comorbidity.
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Substance abuse in schizophrenics carries consequences that further impact
schizophrenic patients. Results of the current study correlate with clinical findings that
amphetamine increases dopaminergic transmission in schizophrenic patients, and that
increases in dopaminergic transmission are associated with a worsening of behavioral
symptoms of schizophrenia. This model may then allow for further exploration of
mechanism(s) that result in a greater incidence of drug use, particularly
psychostimulants, in schizophrenics compared to the general population.
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